

Gregory Lip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6016108/publications.pdf>

Version: 2024-02-01

1,781
papers

148,151
citations

228

145
h-index

114

342
g-index

1815
all docs

1815
docs citations

1815
times ranked

65985
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
2	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
3	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
4	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. <i>Chest</i> , 2010, 137, 263-272.	0.4	5,657
5	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
6	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010, 31, 2369-2429.	1.0	4,635
7	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. <i>Chest</i> , 2010, 138, 1093-1100.	0.4	3,810
8	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
9	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
10	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
11	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
12	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	13.9	2,207
13	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1953-2041.	0.3	2,129
14	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	1.0	1,996
15	Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. <i>European Heart Journal</i> , 2006, 27, 949-953.	1.0	1,640
16	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
17	Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. <i>Lancet</i> , 2007, 370, 493-503.	6.3	1,466
18	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016, 375, 2423-2434.	13.9	1,265

#	ARTICLE	IF	CITATIONS
19	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2011, 342, d124-d124.	2.4	1,143
20	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	13.9	1,099
21	Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. <i>European Heart Journal</i> , 2013, 34, 2746-2751.	1.0	987
22	Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. <i>European Heart Journal</i> , 2012, 33, 1500-1510.	1.0	968
23	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
24	Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 173-180.	1.2	898
25	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2012, 141, e531S-e575S.	0.4	891
26	Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. <i>Lancet, The</i> , 2009, 373, 155-166.	6.3	873
27	Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2012, 367, 625-635.	13.9	795
28	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Europace</i> , 2018, 20, e1-e160.	0.7	767
29	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
30	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
31	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018, 36, 2284-2309.	0.3	689
32	Inflammation in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2263-2270.	1.2	644
33	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	3.8	515
34	Quality of Life in Patients with Atrial Fibrillation: A Systematic Review. <i>American Journal of Medicine</i> , 2006, 119, 448.e1-448.e19.	0.6	502
35	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
36	Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. <i>Lancet, The</i> , 2014, 384, 2235-2243.	6.3	475

#	ARTICLE	IF	CITATIONS
37	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. <i>Europace</i> , 2016, 18, 1455-1490.	0.7	471
38	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453
39	Identifying Patients at High Risk for Stroke Despite Anticoagulation. <i>Stroke</i> , 2010, 41, 2731-2738.	1.0	448
40	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. <i>Heart Rhythm</i> , 2017, 14, e3-e40.	0.3	442
41	Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin. <i>Chest</i> , 2013, 144, 1555-1563.	0.4	440
42	Cardiac Fibrosis in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 943-959.	1.2	427
43	The ABC pathway: an integrated approach to improve AF management. <i>Nature Reviews Cardiology</i> , 2017, 14, 627-628.	6.1	419
44	The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1172-1179.	1.8	414
45	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 739-749.	1.8	393
46	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. <i>PLoS ONE</i> , 2013, 8, e63479.	1.1	375
47	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ</i> , The, 2016, 353, i3189.	3.0	351
48	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
49	Stroke prevention in atrial fibrillation: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1230-1239.	1.8	346
50	Atrial fibrillation. <i>Lancet</i> , The, 2012, 379, 648-661.	6.3	337
51	The Global Burden of Atrial Fibrillation and Stroke. <i>Chest</i> , 2012, 142, 1489-1498.	0.4	335
52	Cancer and the prothrombotic state. <i>Lancet Oncology</i> , The, 2002, 3, 27-34.	5.1	332
53	Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. <i>PLoS Medicine</i> , 2020, 17, e1003321.	3.9	331
54	Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. <i>European Heart Journal</i> , 2015, 36, 1660-1668.	1.0	329

#	ARTICLE	IF	CITATIONS
55	Stroke prevention in atrial fibrillation. <i>Lancet</i> , The, 2016, 388, 806-817.	6.3	329
56	Use of the CHA ₂ DS ₂ -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 860-865.	1.6	327
57	Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 383.	2.4	326
58	Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 861-867.	1.2	326
59	Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2013, 62, 981-989.	1.2	313
60	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2365-2375.	1.2	294
61	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
62	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012, 107, 584-589.	1.8	289
63	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	0.7	280
64	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2015, 350, h1618-h1618.	3.0	279
65	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j510.	2.4	275
66	Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 738-746.	1.2	272
67	Assessment of the CHA ₂ DS ₂ -VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1030.	3.8	262
68	Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2471-2482.	1.2	259
69	Stroke Prevention in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1950.	3.8	258
70	Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2075-2082.	1.2	257
71	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	1.2	257
72	Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2008, 51, 818-825.	1.2	256

#	ARTICLE	IF	CITATIONS
73	Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant. <i>Circulation</i> , 2014, 129, 1577-1585.	1.6	256
74	Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <i>Europace</i> , 2007, 9, 1006-1023.	0.7	254
75	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 314-340.	0.7	254
76	Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2003, 107, 3141-3145.	1.6	250
77	The Role of Aspirin in Cardiovascular Prevention. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1829-1843.	1.2	248
78	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ</i> , The, 2015, 351, h4451.	3.0	247
79	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2018, 49, 2933-2944.	1.0	246
80	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	1.2	244
81	Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. <i>American Journal of Medicine</i> , 2015, 128, 509-518.e2.	0.6	242
82	A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 39-48.	1.9	240
83	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
84	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 355-383.	0.5	233
85	Stroke prevention in atrial fibrillation: An Asian perspective. <i>Thrombosis and Haemostasis</i> , 2014, 112, 789-797.	1.8	231
86	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. <i>Circulation</i> , 2015, 132, 517-525.	1.6	225
87	Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 975-986.	1.8	224
88	Should Atrial Fibrillation Patients With an Additional Risk Factor of the CHA2DS2-VASc Score (Beyond) Tj ETQq0 0 0 jgBT /Overlock 10 1,2	1.2	222
89	Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2006, 118, 321-333.	0.8	219
90	Prevalence, Incidence, and Lifetime Risk of Atrial Fibrillation in China. <i>Chest</i> , 2015, 147, 109-119.	0.4	219

#	ARTICLE	IF	CITATIONS
91	Adherence to the "Atrial Fibrillation Better Care"™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , 2022, 122, 406-414.	1.8	219
92	Atrial fibrillation and stroke prevention. <i>Lancet Neurology</i> , The, 2007, 6, 981-993.	4.9	216
93	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010, 31, 1311-1318.	1.0	216
94	New Oral Anticoagulants in Elderly Adults: Evidence from a Meta-Analysis of Randomized Trials. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 857-864.	1.3	216
95	Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. <i>BMJ</i> , The, 2012, 344, e3522-e3522.	3.0	215
96	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <i>American Heart Journal</i> , 2017, 190, 12-18.	1.2	209
97	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (EAACC). <i>European Heart Journal</i> , 2017, 38, 1961-1975.	0.7	209
98	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	208
99	Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	207
100	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2010, 56, 827-837.	1.2	206
101	Edoxaban versus enoxaparin/warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2016, 388, 1995-2003.	6.3	206
102	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
103	Management of atrial fibrillation. <i>Lancet</i> , The, 2007, 370, 604-618.	6.3	205
104	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq0 0 0.0gBT /Ovzok 10 T	0.2	206
105	Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 100, 599-607.	0.2	199
106	Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. <i>The Euro Heart Survey on Atrial Fibrillation</i> . <i>American Heart Journal</i> , 2007, 153, 1006-1012.	1.2	197
107	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
108	Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. <i>American Heart Journal</i> , 2004, 148, 462-466.	1.2	195

#	ARTICLE	IF	CITATIONS
109	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012, 163, 13-19.e1.	1.2	195
110	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
111	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETWORK/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	0.7	193
112	Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. <i>Lancet Neurology</i> , The, 2018, 17, 539-547.	4.9	192
113	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2022, 122, 020-047.	1.8	192
114	Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1339-1348.	1.2	191
115	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014, 35, 1448-1456.	1.0	190
116	Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2555-2561.	1.0	189
117	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	187
118	High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2007, 38, 1229-1237.	1.0	186
119	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2017, 19, 1556-1578.	0.7	186
120	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16016.	18.1	185
121	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
122	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. <i>EuroIntervention</i> , 2020, 15, 1133-1180.	1.4	183
123	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1189-1198.	1.8	182
124	Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 37-47.	1.6	182
125	Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 2494-2503.	1.0	178
126	Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020, 383, 1735-1745.	13.9	178

#	ARTICLE	IF	CITATIONS
127	Hypertension and atrial fibrillation. <i>Journal of Hypertension</i> , 2012, 30, 239-252.	0.3	177
128	Improving Stroke Risk Stratification Using the CHADS ₂ and CHA ₂ DS ₂ -VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring. <i>Stroke</i> , 2011, 42, 1768-1770.	1.0	176
129	Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a "Real-World" Population With Atrial Fibrillation Receiving Anticoagulant Therapy. <i>Chest</i> , 2013, 143, 179-184.	0.4	176
130	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017, 130, 1388-1396.e6.	0.6	172
131	The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS ₂ or CHA ₂ DS ₂ -VASc Scores in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2199-2204.	1.2	171
132	Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. <i>European Heart Journal</i> , 2019, 40, 2313-2323.	1.0	171
133	Improving Stroke Risk Stratification in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2010, 123, 484-488.	0.6	170
134	Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial. <i>PLoS ONE</i> , 2013, 8, e74037.	1.1	165
135	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. <i>Europace</i> , 2015, 17, 24-31.	0.7	164
136	Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1695-1703.	1.8	164
137	The role of monocytes and inflammation in the pathophysiology of heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 1161-1171.	2.9	162
138	Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1151.	3.8	162
139	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 209-218.	1.8	161
140	The CHA ₂ DS ₂ -VASc score identifies those patients with atrial fibrillation and a CHADS ₂ score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	1.0	160
141	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion "an update. <i>Europace</i> , 2020, 22, 184-184.	0.7	160
142	Dabigatran and Warfarin in Vitamin K Antagonist "Naive and "Experienced Cohorts With Atrial Fibrillation. <i>Circulation</i> , 2010, 122, 2246-2253.	1.6	158
143	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation. <i>Circulation</i> , 2018, 137, 832-840.	1.6	158
144	Using the CHA ₂ DS ₂ -VASc Score for Refining Stroke Risk Stratification in "Low-Risk"™ Asian Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1658-1665.	1.2	157

#	ARTICLE	IF	CITATIONS
145	Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. <i>Europace</i> , 2012, 14, 1553-1559.	0.7	156
146	ESC Council on hypertension position document on the management of hypertensive emergencies. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 37-46.	1.4	155
147	Epidemiology of atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2018, 72, e13070.	0.8	154
148	Ethnic Differences in Patient Perceptions of Atrial Fibrillation and Anticoagulation Therapy. <i>Stroke</i> , 2002, 33, 238-242.	1.0	152
149	Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: Effects of an educational intervention programme. <i>International Journal of Cardiology</i> , 2006, 110, 354-358.	0.8	152
150	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
151	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	1.8	149
152	Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 122-132.	1.2	147
153	Platelet indexes in relation to target organ damage in high-risk hypertensive patients. <i>Journal of the American College of Cardiology</i> , 2004, 44, 415-422.	1.2	145
154	Real-World™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. <i>American Journal of Medicine</i> , 2014, 127, 519-529.e1.	0.6	144
155	Antiarrhythmic drugs: clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2018, 20, 731-732.a1.	0.7	144
156	Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. <i>Lancet Neurology</i> , The, 2019, 18, 653-665.	4.9	143
157	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. <i>European Heart Journal</i> , 2017, 38, ehw658.	1.0	142
158	Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. <i>European Heart Journal</i> , 2013, 34, 1041-1049.	1.0	141
159	Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal. <i>International Journal of Cardiology</i> , 2015, 180, 246-254.	0.8	141
160	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1385-1394.	1.2	141
161	Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation. <i>Stroke</i> , 2006, 37, 2294-2300.	1.0	140
162	Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2011, 124, 111-114.	0.6	140

#	ARTICLE	IF	CITATIONS
163	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. <i>European Heart Journal</i> , 2015, 36, 297-306.	1.0	140
164	Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1278-1287.	0.6	139
165	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
166	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	0.7	138
167	Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation. <i>Stroke</i> , 1999, 30, 2547-2553.	1.0	137
168	A 12-Year Follow-up Study of Patients With Newly Diagnosed Lone Atrial Fibrillation. <i>Chest</i> , 2012, 141, 339-347.	0.4	136
169	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015, 128, 1306-1313.e1.	0.6	135
170	Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 380.	2.4	134
171	Effect of hypertension on anticoagulated patients with atrial fibrillation. <i>European Heart Journal</i> , 2007, 28, 752-759.	1.0	133
172	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015, 5, 9902.	1.6	133
173	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	1.0	133
174	Atrial Fibrillation and Cognitive Function. <i>Journal of the American College of Cardiology</i> , 2019, 73, 612-619.	1.2	133
175	Stroke and Thromboembolism in Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 2289-2304.	0.7	131
176	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in real-world clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1072-1082.	1.8	130
177	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 495-504.	1.9	129
178	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. <i>American Journal of Medicine</i> , 2018, 131, 1359-1366.e6.	0.6	129
179	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. <i>Europace</i> , 2015, 17, 1777-1786.	0.7	128
180	Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). <i>American Heart Journal</i> , 2016, 178, 126-134.	1.2	128

#	ARTICLE	IF	CITATIONS
181	Hemoxygenase-1 in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2008, 52, 971-978.	1.2	127
182	Safety and efficacy of well managed warfarin. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1370-1377.	1.8	127
183	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing APCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	1.2	126
184	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2022, 8, 21.	18.1	126
185	Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2015, 191, 172-177.	0.8	125
186	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 955-967.	0.2	124
187	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	0.7	124
188	A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects. <i>Chest</i> , 2019, 155, 510-518.	0.4	124
189	Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 312-318.	2.1	123
190	Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors. <i>Thrombosis and Haemostasis</i> , 2018, 47, 768-777.	1.8	123
191	Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation. <i>Chest</i> , 2018, 153, 453-466.	0.4	122
192	Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2496-2504.	1.2	121
193	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. <i>BMJ, The</i> , 2015, 351, h5876.	3.0	120
194	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2015, 17, 1747-1769.	0.7	119
195	Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 172.	3.0	119
196	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLEACE). <i>Europace</i> , 2017, 19, 465-511.	0.7	118
197	Contemporary stroke prevention strategies in 11%096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	0.7	118
198	The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2021, 121, 270-278.	1.8	118

#	ARTICLE	IF	CITATIONS
199	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2497.	3.8	118
200	Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting. <i>Chest</i> , 2008, 134, 559-567.	0.4	117
201	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 3040-3048.	1.0	117
202	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥ 75 Years With Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 143-150.	1.0	116
203	Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. <i>Annals of Medicine</i> , 2004, 36, 552-557.	1.5	115
204	Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 187-194.	1.8	115
205	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. <i>Journal of Human Hypertension</i> , 2007, 21, 183-211.	1.0	113
206	Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. <i>European Journal of Heart Failure</i> , 2015, 17, 1192-1200.	2.9	113
207	The Global Burden of Atrial Fibrillation and Stroke. <i>Chest</i> , 2017, 152, 810-820.	0.4	113
208	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>American Heart Journal</i> , 2014, 167, 329-334.	1.2	112
209	SAME-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 1083-1088.	0.6	112
210	10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. <i>American Heart Journal</i> , 2018, 202, 20-26.	1.2	112
211	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. <i>BMJ, The</i> , 2012, 345, e7097-e7097.	3.0	110
212	Renal Impairment in a Real-Life Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). <i>American Journal of Cardiology</i> , 2013, 111, 1159-1164.	0.7	110
213	Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. <i>European Heart Journal</i> , 2008, 29, 915-922.	1.0	109
214	Relationship of the SAME-TT 2 R 2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation. <i>Chest</i> , 2014, 146, 719-726.	0.4	108
215	Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1452-1464.	1.2	107
216	Novel Risk Markers and Risk Assessments for Cardiovascular Disease. <i>Circulation Research</i> , 2017, 120, 133-149.	2.0	107

#	ARTICLE	IF	CITATIONS
217	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología). <i>Europace</i> , 2017, 19, 1757-1758.	0.7	107
218	How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. <i>Europace</i> , 2022, 24, 979-1005.	0.7	107
219	The role of aspirin for stroke prevention in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2011, 8, 602-606.	6.1	106
220	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	1.0	106
221	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014, 16, 1655-1673.	0.7	105
222	Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. <i>Heart Rhythm</i> , 2014, 11, 1401-1408.	0.3	105
223	Elevated Platelet Microparticle Levels in Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2007, 131, 809-815.	0.4	104
224	Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1339-1347.	1.2	104
225	Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. <i>Circulation</i> , 2016, 133, 1540-1547.	1.6	103
226	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 956-960.	1.8	102
227	Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?. <i>Stroke</i> , 2017, 48, 857-866.	1.0	102
228	P-Wave Indices and Risk of Ischemic Stroke. <i>Stroke</i> , 2017, 48, 2066-2072.	1.0	102
229	Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 98-106.	1.0	102
230	Endothelial Dysfunction: Methods of Assessment and Application to Hypertension. <i>Current Pharmaceutical Design</i> , 2004, 10, 3591-3605.	0.9	101
231	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. <i>American Journal of Medicine</i> , 2016, 129, 600-607.	0.6	101
232	Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 970-976.	1.0	101
233	Ideal Blood Pressure in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1233-1245.	1.2	101
234	Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. <i>Thrombosis and Haemostasis</i> , 2006, 96, 45-52.	1.8	100

#	ARTICLE	IF	CITATIONS
235	Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 650-656.e5.	0.6	100
236	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. <i>Thrombosis and Haemostasis</i> , 2015, 114, 826-834.	1.8	100
237	Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 3354-3361.	1.0	100
238	Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a real-world observational study in the United States. <i>International Journal of Clinical Practice</i> , 2016, 70, 752-763.	0.8	100
239	Atrial Fibrillation and Hypertension. <i>Hypertension</i> , 2017, 70, 854-861.	1.3	100
240	Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. <i>Heart</i> , 2018, 104, 2010-2017.	1.2	100
241	Heart rate variability in atrial fibrillation: The balance between sympathetic and parasympathetic nervous system. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13174.	1.7	100
242	Edoxaban: a focused review of its clinical pharmacology. <i>European Heart Journal</i> , 2014, 35, 1844-1855.	1.0	99
243	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 981-988.	1.8	99
244	Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. <i>Annals of Medicine</i> , 2005, 37, 61-66.	1.5	98
245	Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1106-1115.	1.8	98
246	Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1074-1079.	1.8	98
247	Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1711-1714.	1.9	97
248	Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1296-1304.	1.8	97
249	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , 2012, 14, 295-301.	2.9	96
250	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 1268-1276.	1.0	96
251	A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: The Belgrade Atrial Fibrillation Study. <i>International Journal of Cardiology</i> , 2013, 168, 4744-4749.	0.8	95
252	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95

#	ARTICLE	IF	CITATIONS
253	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3295-3308.	1.2	95
254	Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). <i>American Journal of Cardiology</i> , 2003, 92, 400-405.	0.7	94
255	Patient outcomes using the European label for dabigatran. <i>Thrombosis and Haemostasis</i> , 2014, 112, 933-942.	1.8	94
256	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2019, 156, 529-543.	0.4	94
257	Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. <i>European Journal of Internal Medicine</i> , 2020, 82, 105-111.	1.0	94
258	Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. <i>Stroke</i> , 2003, 34, 1181-1186.	1.0	93
259	Edoxaban in Asian Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 838-853.	1.2	93
260	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. <i>Journal of Arrhythmia</i> , 2016, 32, 247-278.	0.5	92
261	CHA ₂ DS ₂ -VASc Score (Congestive Heart Failure, Hypertension, Age ≥75) Tj ETQq1 1 0.784314 rgBT	1.0	92
262	Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 100.	2.7	92
263	Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 640.e9-640.e17.	0.6	91
264	Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. <i>International Journal of Cardiology</i> , 2017, 227, 644-649.	0.8	91
265	Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin. <i>Stroke</i> , 2015, 46, 23-30.	1.0	90
266	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. <i>PLoS Medicine</i> , 2019, 16, e1002903.	3.9	90
267	From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. <i>Journal of Human Hypertension</i> , 2016, 30, 463-466.	1.0	89
268	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018, 14, 337-351.	4.1	89
269	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1261-1267.	1.4	89
270	A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1926-1931.	1.2	88

#	ARTICLE	IF	CITATIONS
271	Plasma angiotensin-converting enzyme, angiotensin II and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. <i>European Journal of Clinical Investigation</i> , 2003, 33, 883-890.	1.7	88
272	Atrial Fibrillation and the Prothrombotic State in the Elderly. <i>Stroke</i> , 2003, 34, 413-417.	1.0	88
273	Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. <i>European Heart Journal</i> , 2009, 30, 2897-2907.	1.0	88
274	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 418-429.	1.5	87
275	Management of atrial fibrillation. <i>Heart</i> , 2006, 92, 1177-1182.	1.2	86
276	Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	86
277	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
278	Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 1803-1810.	1.0	86
279	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017, 135, 323-333.	1.6	86
280	Relation of Gender-Specific Risk of Ischemic Stroke in Patients With Atrial Fibrillation to Differences in Warfarin Anticoagulation Control (from AFFIRM). <i>American Journal of Cardiology</i> , 2012, 110, 1799-1802.	0.7	85
281	One-Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry. <i>Clinical Cardiology</i> , 2014, 37, 357-364.	0.7	85
282	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017, 19, 169-179.	0.7	84
283	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2376-2388.	1.8	84
284	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014932.	1.6	84
285	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	0.8	83
286	Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. <i>Journal of Internal Medicine</i> , 2018, 283, 45-55.	2.7	83
287	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). <i>American Journal of Hypertension</i> , 2004, 17, 764-769.	1.0	82
288	Anticoagulant and Antiplatelet Therapy Use in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Chest</i> , 2006, 130, 1823-1827.	0.4	81

#	ARTICLE	IF	CITATIONS
289	Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 344-351.	1.9	81
290	Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. <i>Heart</i> , 2004, 90, 1162-1166.	1.2	80
291	Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation. <i>Chest</i> , 2016, 149, 401-412.	0.4	80
292	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in Denmark. <i>Scientific Reports</i> , 2016, 6, 31477.	1.6	80
293	Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	80
294	Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. <i>European Heart Journal</i> , 2019, 40, 809-819.	1.0	80
295	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020, 133, 1195-1202.e2.	0.6	80
296	Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. <i>European Journal of Clinical Investigation</i> , 2003, 33, 941-948.	1.7	79
297	Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at “moderate risk”™ [CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. <i>Thrombosis and Haemostasis</i> , 2010, 103, 683-685.	1.8	79
298	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , 2017, 89, 687-696.	1.5	79
299	Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 339-347.	0.5	78
300	Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. <i>European Heart Journal</i> , 2014, 35, 1897-1906.	1.0	78
301	Validation of a Modified CHA ₂ DS ₋ VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 2462-2469.	1.0	78
302	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 412-420.	1.5	78
303	C ₂ HEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study. <i>Journal of the American Heart Association</i> , 2019, 8, e012546.	1.6	78
304	Patients With Ischemic Stroke and Incident Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2432-2437.	1.0	77
305	Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2020, 41, 4483-4493.	1.0	77
306	Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. <i>Diabetic Medicine</i> , 2005, 22, 1657-1662.	1.2	76

#	ARTICLE	IF	CITATIONS
307	Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: Thrombosis Research, 2008, 122, 85-90.	0.8	76
308	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Internal Medicine, 2017, 177, 563.	2.6	75
309	Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. European Heart Journal, 2013, 34, 3572-3579.	1.0	74
310	Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm, 2014, 11, 1752-1759.	0.3	74
311	Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Clinical Therapeutics, 2014, 36, 192-210.e20.	1.1	74
312	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis and Haemostasis, 2017, 117, 1448-1454.	1.8	74
313	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace, 2021, 23, 174-183.	0.7	74
314	Oxidative stress in malignant and non-malignant phase hypertension. Journal of Human Hypertension, 2002, 16, 333-336.	1.0	73
315	Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. International Journal of Cardiology, 2016, 204, 88-94.	0.8	73
316	Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Stroke, 2019, 50, 2245-2249.	1.0	73
317	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. Stroke, 2015, 46, 2168-2174.	1.0	72
318	Role of Monocytes in Heart Failure and Atrial Fibrillation. Journal of the American Heart Association, 2018, 7, .	1.6	72
319	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight. Journal of the American College of Cardiology, 2019, 73, 919-931.	1.2	72
320	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 2012, 14, 681-695.	2.9	71
321	Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: The MB-LATER clinical score. Scientific Reports, 2017, 7, 40828.	1.6	71
322	CHA ₂ DS ₂ -VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke. Stroke, 2017, 48, 2984-2990.	1.0	71
323	The prothrombotic state in atrial fibrillation: pathophysiological and management implications. Cardiovascular Research, 2019, 115, 31-45.	1.8	71
324	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. PLoS ONE, 2017, 12, e0189495.	1.1	71

#	ARTICLE	IF	CITATIONS
325	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe. <i>Thrombosis and Haemostasis</i> , 2011, 106, 569-571.	1.8	70
326	Prognosis and Guideline-Adherent Antithrombotic Treatment in Patients With Atrial Fibrillation and Atrial Flutter. <i>Chest</i> , 2011, 140, 911-917.	0.4	70
327	Patent Foramen Ovale and Migraine Attacks: A Systematic Review. <i>American Journal of Medicine</i> , 2014, 127, 411-420.	0.6	70
328	Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. <i>Heart</i> , 2020, 106, 1463-1468.	1.2	70
329	Cardiac arrhythmias in patients with COVID-19. <i>Journal of Arrhythmia</i> , 2020, 36, 827-836.	0.5	70
330	Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. <i>International Journal of Cardiology</i> , 1995, 51, 245-251.	0.8	69
331	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69
332	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. <i>PLoS ONE</i> , 2015, 10, e0122520.	1.1	69
333	Assessing the Risk of Bleeding in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 941-948.	2.1	68
334	Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. <i>European Journal of Heart Failure</i> , 2012, 14, 211-218.	2.9	68
335	Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015, 17, 570-582.	2.9	68
336	Current Understanding of Atherogenesis. <i>American Journal of Medicine</i> , 2017, 130, 268-282.	0.6	68
337	Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. <i>Stroke</i> , 2018, 49, 2301-2308.	1.0	68
338	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
339	Coagulopathic complications in breast cancer. <i>Cancer</i> , 2003, 98, 1578-1586.	2.0	67
340	Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2067-2076.	1.2	67
341	Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk Prediction Scores in Nonwarfarin Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2013, 61, 386-387.	1.2	67
342	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017, 19, euw242.	0.7	67

#	ARTICLE	IF	CITATIONS
343	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016, 6, 27410.	1.6	67
344	Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. <i>Age and Ageing</i> , 2018, 47, 9-17.	0.7	67
345	Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially "Low-Risk" Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1162-1170.	1.8	67
346	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , 2019, 132, 856-861.	0.6	67
347	Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. <i>Cardiovascular Research</i> , 2021, 117, 1-21.	1.8	67
348	Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 795-802.	0.2	66
349	A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation. <i>Chest</i> , 2014, 145, 1370-1382.	0.4	66
350	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2427-2436.	1.4	66
351	Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy. <i>Current Pharmaceutical Design</i> , 2006, 12, 1581-1592.	0.9	65
352	A contemporary view on endothelial function in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 873-881.	2.9	65
353	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	1.8	65
354	Design and Rationale of the "DUAL PCI" Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	0.7	65
355	Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. <i>Circulation</i> , 2018, 138, 1485-1487.	1.6	65
356	Pathophysiology of atrial fibrillation and chronic kidney disease. <i>Cardiovascular Research</i> , 2021, 117, 1046-1059.	1.8	65
357	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. <i>Circulation</i> , 2022, 145, 392-409.	1.6	65
358	Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 381-383.	1.8	64
359	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. <i>Journal of Internal Medicine</i> , 2015, 278, 1-18.	2.7	64
360	Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. <i>International Journal of Stroke</i> , 2016, 11, 302-312.	2.9	64

#	ARTICLE	IF	CITATIONS
361	Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. <i>European Heart Journal</i> , 2019, 40, 1504-1514.	1.0	64
362	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021, 23, 494-495.	0.7	64
363	Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. <i>BMJ, The</i> , 2021, 373, n991.	3.0	64
364	Myocardial Ischemic Events in "Real World"™ Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin. <i>American Journal of Medicine</i> , 2014, 127, 329-336.e4.	0.6	63
365	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. <i>Clinical Research in Cardiology</i> , 2016, 105, 912-920.	1.5	63
366	Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes. <i>American Journal of Hypertension</i> , 2017, 30, 733-755.	1.0	63
367	Epidemiology of Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 1-23.	0.7	63
368	Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 330-339.	1.8	63
369	Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13679.	1.7	63
370	Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. <i>International Journal of Cardiology</i> , 2018, 254, 157-161.	0.8	62
371	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	1.0	62
372	Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. <i>Heart Rhythm</i> , 2020, 17, 2102-2110.	0.3	62
373	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Europace</i> , 2020, 22, 1147-1148.	0.7	62
374	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	0.8	62
375	Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. <i>British Journal of Ophthalmology</i> , 2004, 88, 1543-1546.	2.1	61
376	"Real-world"™ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme "Atrial Fibrillation (EORP-AF) General Pilot Registry. <i>Europace</i> , 2016, 18, 648.1-657.	0.7	61
377	Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. <i>Clinical Research in Cardiology</i> , 2017, 106, 813-823.	1.5	61
378	Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). <i>Europace</i> , 2019, 21, 1603-1604.	0.7	61

#	ARTICLE	IF	CITATIONS
379	Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 459-466.	1.4	60
380	Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1236-1244.	0.9	60
381	Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: The Chin-Shan Community Cohort Study. <i>International Journal of Cardiology</i> , 2013, 168, 414-419.	0.8	59
382	Rationale and design of the Chinese Atrial Fibrillation Registry Study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 130.	0.7	59
383	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA ₂ DS ₂ -VASc Risk Factor Be Anticoagulated?. <i>Stroke</i> , 2016, 47, 1831-1836.	1.0	59
384	Platelet-derived VEGF, Flt ₁ , Angiopoietin ₁ and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. <i>Annals of Medicine</i> , 2004, 36, 273-277.	1.5	58
385	Antithrombotic treatment in atrial fibrillation. <i>Postgraduate Medical Journal</i> , 2008, 84, 252-258.	0.9	58
386	Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, 653-656.	1.0	58
387	Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 35-42.	1.8	58
388	Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e014177.	1.6	58
389	The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review. <i>Clinical Therapeutics</i> , 2014, 36, 1135-1144.	1.1	57
390	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2523-2528.	1.0	57
391	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , 2015, 44, 874-878.	0.7	57
392	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1901-1919.	1.8	57
393	Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2020, 173, 1-9.	2.0	57
394	Risk factors and stroke risk stratification for atrial fibrillation: Limitations and new possibilities. <i>American Heart Journal</i> , 2008, 156, 1-3.	1.2	56
395	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 328-336.	1.8	56
396	Long-term bleeding risk prediction in "real world" patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1848-1858.	1.8	56

#	ARTICLE	IF	CITATIONS
397	Atrial Fibrillation in Older People: Concepts and Controversies. <i>Frontiers in Medicine</i> , 2019, 6, 175.	1.2	56
398	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAFâ€‘App) II randomised trial. <i>International Journal of Clinical Practice</i> , 2019, 73, e13352.	0.8	56
399	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy. <i>Chest</i> , 2019, 155, 354-363.	0.4	56
400	Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2490.	1.0	56
401	Chronic Kidney Disease and Cerebrovascular Disease. <i>Stroke</i> , 2021, 52, e328-e346.	1.0	56
402	Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2002, 90, 1258-1260.	0.7	55
403	Circulating microparticles: challenges and perspectives of flow cytometric assessment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1009-1014.	1.8	55
404	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 19188.	1.6	55
405	Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor. <i>Chest</i> , 2016, 149, 960-968.	0.4	55
406	â€‘Real-worldâ€™ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2016, 19, euw112.	0.7	55
407	A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. <i>Europace</i> , 2016, 18, euw069.	0.7	55
408	Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 271-282.	1.2	55
409	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. <i>Journal of Human Hypertension</i> , 2019, 33, 824-836.	1.0	55
410	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	1.8	55
411	COVIDâ€‘19 and ischemic stroke. <i>European Journal of Neurology</i> , 2021, 28, 3826-3836.	1.7	55
412	Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>PLoS ONE</i> , 2014, 9, e114445.	1.1	54
413	The Impact of Smoking on Thromboembolism and Mortality in Patients With Incident Atrial Fibrillation. <i>Chest</i> , 2014, 145, 559-566.	0.4	54
414	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , 2015, 101, 1446-1455.	1.2	54

#	ARTICLE	IF	CITATIONS
415	Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review. <i>Eye</i> , 2016, 30, 1031-1038.	1.1	54
416	Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. <i>Europace</i> , 2016, 18, 1308-1318.	0.7	54
417	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. <i>Europace</i> , 2020, 22, 33-46.	0.7	54
418	Prognostic value of CHA ₂ DS ₂ -VASc score in patients with non-valvular atrial fibrillation and valvular heart disease: the Loire Valley Atrial Fibrillation Project. <i>European Heart Journal</i> , 2015, 36, 1822.2-1830.	1.0	53
419	Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. <i>International Journal of Cardiology</i> , 2018, 269, 182-191.	0.8	53
420	Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1038-1048.	1.9	53
421	Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation. <i>American Journal of Hypertension</i> , 2004, 17, 770-774.	1.0	52
422	Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. <i>Journal of Internal Medicine</i> , 2008, 264, 50-61.	2.7	52
423	Bridging Evidence-Based Practice and Practice-Based Evidence in Periprocedural Anticoagulation. <i>Circulation</i> , 2012, 126, 1573-1576.	1.6	52
424	Safety of new oral anticoagulant drugs: a perspective. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 8-20.	1.0	52
425	Exercise-induced changes in inflammatory processes: Implications for thrombogenesis in cardiovascular disease. <i>Annals of Medicine</i> , 2014, 46, 439-455.	1.5	52
426	Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 326-334.	1.3	52
427	Unreal world or real world data in oral anticoagulant treatment of atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 587-589.	1.8	52
428	Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. <i>Journal of Physiology</i> , 2017, 595, 967-981.	1.3	52
429	Best Practice for Atrial Fibrillation Patient Education. <i>Current Pharmaceutical Design</i> , 2014, 21, 533-543.	0.9	52
430	Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA ₂ DS ₂ -VASc risk stratification scores. <i>Age and Ageing</i> , 2010, 39, 533-535.	0.7	51
431	Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>BMJ Open</i> , 2012, 2, e000975.	0.8	51
432	Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study. <i>European Journal of Heart Failure</i> , 2013, 15, 415-424.	2.9	51

#	ARTICLE	IF	CITATIONS
433	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , 2013, 99, 1093-1099.	1.2	51
434	Prior History of Falls and Risk of Outcomes in Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. <i>American Journal of Medicine</i> , 2014, 127, 972-978.	0.6	51
435	The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. <i>International Journal of Stroke</i> , 2015, 10, 155-161.	2.9	51
436	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective "Real-world" Inception Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 1237-1243.	0.6	51
437	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016, 6, 30271.	1.6	51
438	Malignant Hypertension Revisited"Does This Still Exist?. <i>American Journal of Hypertension</i> , 2017, 30, 543-549.	1.0	51
439	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2261-2266.	1.8	51
440	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018, 55, 28-34.	1.0	51
441	Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. <i>European Journal of Epidemiology</i> , 2019, 34, 173-190.	2.5	51
442	Improving Stroke Risk Prediction in the General Population: A Comparative Assessment of Common Clinical Rules, a New Multimorbid Index, and Machine-Learning-Based Algorithms. <i>Thrombosis and Haemostasis</i> , 2022, 122, 142-150.	1.8	51
443	Myocardial Perfusion by Myocardial Contrast Echocardiography and Endothelial Dysfunction in Obstructive Sleep Apnea. <i>Hypertension</i> , 2011, 58, 417-424.	1.3	50
444	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 617-624.	1.8	50
445	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight"a systematic literature review. <i>Clinical Research in Cardiology</i> , 2017, 106, 565-572.	1.5	50
446	Left ventricular thrombosis: new perspectives on an old problem. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 158-167.	1.4	50
447	Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. <i>BMJ: British Medical Journal</i> , 2008, 336, 614-615.	2.4	49
448	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , 2016, 6, 24376.	1.6	49
449	β -Blockers in Atrial Fibrillation Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002597.	1.6	49
450	Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018, 131, 185-192.	0.6	49

#	ARTICLE	IF	CITATIONS
451	Hypertension, left ventricular hypertrophy, and sudden death. <i>Current Cardiology Reports</i> , 2002, 4, 449-457.	1.3	48
452	Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. <i>BMJ Open</i> , 2012, 2, e001768.	0.8	48
453	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	1.0	48
454	Discontinuation risk comparison among “real-world” newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018, 13, e0195950.	1.1	48
455	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019, 50, 1372-1379.	1.0	48
456	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019, 35, 619-633.	0.8	48
457	Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. <i>Ageing Research Reviews</i> , 2022, 79, 101652.	5.0	48
458	Persistent Macrovascular and Microvascular Dysfunction in Patients With Malignant Hypertension. <i>Hypertension</i> , 2011, 57, 490-496.	1.3	47
459	A proposal for new clinical concepts in the management of atrial fibrillation. <i>American Heart Journal</i> , 2012, 164, 292-302.e1.	1.2	47
460	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 975-987.	1.9	47
461	Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAME-TT ₂ R ₂ score. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 150-152.	1.4	47
462	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. <i>Europace</i> , 2017, 19, 1439-1448.	0.7	47
463	Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018, 13, e0205989.	1.1	47
464	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	0.7	47
465	Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 320-325.	0.9	47
466	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Intracranial Bleeding in Asian Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2014, 78, 2367-2372.	0.7	46
467	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. <i>American Journal of Medicine</i> , 2018, 131, 574.e13-574.e27.	0.6	46
468	Heart failure in a multiethnic population in Kuala Lumpur, Malaysia. <i>European Journal of Heart Failure</i> , 2003, 5, 569-574.	2.9	45

#	ARTICLE	IF	CITATIONS
469	Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block. The Cochrane Library, 2004, , CD003710.	1.5	45
470	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk Score Acronyms (CHADS ₂ , CHA ₂ DS ₂ -VASc, R ₂ CHADS ₂), Tj ETQq000rgB15/Overlock	1.0	45
471	Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation. Stroke, 2016, 47, 2707-2713.	1.0	45
472	Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review. Seminars in Thrombosis and Hemostasis, 2017, 43, 849-863.	1.5	45
473	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2017, 31, 419-431.	1.3	45
474	Blood Pressure Variability and Incidence of New-Onset Atrial Fibrillation. Hypertension, 2020, 75, 309-315.	1.3	45
475	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer, 2021, 127, 2122-2129.	2.0	45
476	Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new "vascular triad"™. Annals of Medicine, 2004, 36, 119-125.	1.5	44
477	Type 2 diabetes mellitus: a cardiovascular perspective. International Journal of Clinical Practice, 2005, 59, 798-816.	0.8	44
478	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor. JAMA Cardiology, 2017, 2, 872.	3.0	44
479	Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. American Journal of Cardiology, 2017, 120, 1139-1145.	0.7	44
480	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. Korean Circulation Journal, 2018, 48, 665.	0.7	44
481	Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurology, The, 2021, 20, 842-853.	4.9	44
482	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. Chest, 2015, 147, 1651-1658.	0.4	43
483	Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. International Journal of Cardiology, 2016, 207, 258-263.	0.8	43
484	The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Europace, 2020, 22, 547-557.	0.7	43
485	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460.	1.0	43
486	Acute Management of Atrial Fibrillation. Chest, 2009, 135, 849-859.	0.4	42

#	ARTICLE	IF	CITATIONS
487	Heparin Bridging vs. Uninterrupted Oral Anticoagulation in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting. <i>Circulation Journal</i> , 2012, 76, 1363-1368.	0.7	42
488	Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	42
489	Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. <i>Clinical Cardiology</i> , 2017, 40, 222-229.	0.7	42
490	Ethnic differences in the prevalence of peripheral arterial disease: a systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 327-338.	0.6	42
491	Long-term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA ₂ DS ₂ -VASc Scores. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
492	Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 2421-2429.	1.0	42
493	Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. <i>Stroke</i> , 2020, 51, 416-423.	1.0	42
494	Mobile health solutions for atrial fibrillation detection and management: a systematic review. <i>Clinical Research in Cardiology</i> , 2022, 111, 479-491.	1.5	42
495	Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation. <i>American Journal of Hypertension</i> , 2004, 17, 770-774.	1.0	41
496	Atrial fibrillation post-cardiac surgery: changing perspectives. <i>Current Medical Research and Opinion</i> , 2006, 22, 1437-1441.	0.9	41
497	Added Predictive Ability of the CHA ₂ DS ₂ VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 335-342.	0.9	41
498	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	0.7	41
499	Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study. <i>Heart Rhythm</i> , 2016, 13, 1581-1588.	0.3	41
500	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236.	1.8	41
501	Anticoagulation Resumption After Intracerebral Hemorrhage. <i>Current Atherosclerosis Reports</i> , 2018, 20, 32.	2.0	41
502	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. <i>Journal of Arrhythmia</i> , 2018, 34, 99-123.	0.5	41
503	Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019, 50, 2574-2577.	1.0	41
504	Body Mass Index Variability and Long-term Risk of New-Onset Atrial Fibrillation in the General Population: A Korean Nationwide Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 225-235.	1.4	41

#	ARTICLE	IF	CITATIONS
505	Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1662-1671.	1.3	41
506	The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study. <i>Europace</i> , 2020, 22, 90-99.	0.7	41
507	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1200-1207.	1.8	41
508	Use of the SAME-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. <i>PLoS ONE</i> , 2016, 11, e0150674.	1.1	41
509	Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 171-174.	2.9	40
510	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. <i>Chest</i> , 2015, 148, 62-72.	0.4	40
511	Stroke prevention in atrial fibrillation and "real world" adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016, 6, 20432.	1.6	40
512	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. <i>American Journal of Medicine</i> , 2017, 130, 135-145.	0.6	40
513	Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. <i>American Heart Journal</i> , 2018, 198, 55-63.	1.2	40
514	EHRA White Paper: knowledge gaps in arrhythmia management" status 2019. <i>Europace</i> , 2019, 21, 993-994.	0.7	40
515	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Journal of Arrhythmia</i> . 2020, 36, 553-607.	0.5	40
516	Small Vessel Disease and Ischemic Stroke Risk During Anticoagulation for Atrial Fibrillation After Cerebral Ischemia. <i>Stroke</i> , 2021, 52, 91-99.	1.0	40
517	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605,771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f11-f19.	1.4	40
518	Relationship between lipoproteins, thrombosis, and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 716-731.	1.8	40
519	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021, 86, 1-11.	1.0	40
520	Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. <i>Nutrients</i> , 2022, 14, 103.	1.7	40
521	Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes. <i>European Heart Journal</i> , 2007, 28, 1092-1101.	1.0	39
522	Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation. <i>Chest</i> , 2008, 134, 574-581.	0.4	39

#	ARTICLE	IF	CITATIONS
523	Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. <i>Europace</i> , 2012, 14, 184-190.	0.7	39
524	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 696-701.	1.0	39
525	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	39
526	Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1573-1583.	1.2	39
527	Quality of oral anticoagulation with vitamin K antagonists in "real-world" patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018, 20, 1435-1441.	0.7	39
528	Genotype-guided warfarin dosing vs conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1868-1882.	1.1	39
529	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007030.	2.1	39
530	Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function. <i>Stroke</i> , 2019, 50, 1140-1148.	1.0	39
531	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 348-357.	0.4	39
532	Obesity and atrial fibrillation: making inroads through fat. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 59-67.	1.4	39
533	Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. <i>Europace</i> , 2022, 24, 20-30.	0.7	39
534	How machine learning is impacting research in atrial fibrillation: implications for risk prediction and future management. <i>Cardiovascular Research</i> , 2021, 117, 1700-1717.	1.8	39
535	Measurement of the soluble angiotensin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. <i>European Journal of Clinical Investigation</i> , 2003, 33, 529-535.	1.7	38
536	The effects of coronary artery disease severity on time-dependent changes in platelet activation indices in stored whole blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 135-140.	1.0	38
537	Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 177-194.	1.6	38
538	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>American Heart Journal</i> , 2016, 181, 83-91.	1.2	38
539	Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2019, 8, e011358.	1.6	38
540	Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2021, 107, 1630-1636.	1.2	38

#	ARTICLE	IF	CITATIONS
541	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021, 37, 1389-1426.	0.5	38
542	Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. <i>Heart</i> , 2005, 91, 759-763.	1.2	37
543	Development of a Novel Composite Stroke and Bleeding Risk Score in Patients With Atrial Fibrillation. <i>Chest</i> , 2013, 144, 1839-1847.	0.4	37
544	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. <i>British Journal of General Practice</i> , 2015, 65, e16-e23.	0.7	37
545	Effects of Aspirin on Endothelial Function and Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 83.	1.5	37
546	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	0.8	37
547	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , 2018, 261, 92-98.	0.8	37
548	Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy. <i>Circulation</i> , 2018, 137, 1117-1129.	1.6	37
549	Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 285-293.	1.8	37
550	Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. <i>JAMA Network Open</i> , 2020, 3, e206424.	2.8	37
551	Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. <i>Lancet Neurology</i> , The, 2021, 20, 294-303.	4.9	37
552	Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1961-1973.	0.8	37
553	Inflammasome Signaling in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2349-2366.	1.2	37
554	Quality of life in older people with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009, 25, 37-42.	0.6	36
555	Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: The Chin-Shan Community Cohort Study. <i>International Journal of Cardiology</i> , 2013, 168, 1832-1836.	0.8	36
556	Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. <i>International Journal of Cardiology</i> , 2014, 170, 303-308.	0.8	36
557	Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. <i>Clinical Research in Cardiology</i> , 2015, 104, 1088-1096.	1.5	36
558	Recurrent Stroke. <i>Stroke</i> , 2015, 46, 2491-2497.	1.0	36

#	ARTICLE	IF	CITATIONS
559	Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. <i>European Heart Journal</i> , 2015, 36, ehv415.	1.0	36
560	Drug-drug interactions of non-vitamin K oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1445-1461.	1.5	36
561	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. <i>Lancet Haematology</i> , 2017, 4, e237-e244.	2.2	36
562	Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. <i>American Heart Journal</i> , 2017, 194, 99-106.	1.2	36
563	Microparticles and cardiovascular diseases. <i>Annals of Medicine</i> , 2019, 51, 193-223.	1.5	36
564	Stroke prevention strategies in high-risk patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2021, 18, 276-290.	6.1	36
565	Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. <i>European Heart Journal</i> , 2021, 42, 4759-4768.	1.0	36
566	Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). <i>PLoS ONE</i> , 2016, 11, e0147065.	1.1	36
567	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke. <i>Stroke</i> , 2022, 53, 1759-1763.	1.0	36
568	A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. <i>American Journal of Hypertension</i> , 2001, 14, 823-828.	1.0	35
569	Ethnic differences in patient perceptions of heart failure and treatment: the West Birmingham heart failure project. <i>Heart</i> , 2004, 90, 1016-1019.	1.2	35
570	Aspirin and aspirin resistance in coronary artery disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 242-250.	1.7	35
571	Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact?. <i>International Journal of Cardiology</i> , 2013, 168, 515-522.	0.8	35
572	Current practice for diagnosis and management of silent atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 1223-1225.	0.7	35
573	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a "real-world" community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1032-1038.	1.7	35
574	Stroke Prevention With Oral Anticoagulation Therapy in Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2013, 77, 1380-1388.	0.7	35
575	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2015, 79, 339-345.	0.7	35
576	Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1115.	3.8	35

#	ARTICLE	IF	CITATIONS
577	Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. <i>Thrombosis Research</i> , 2017, 153, 19-27.	0.8	35
578	Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. <i>Journal of Internal Medicine</i> , 2021, 289, 42-52.	2.7	35
579	Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e94420.	1.1	35
580	Viewpoint: The prothrombotic state in heart failure: A maladaptive inflammatory response?. <i>European Journal of Heart Failure</i> , 2007, 9, 124-128.	2.9	34
581	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. <i>Chest</i> , 2014, 146, 1337-1346.	0.4	34
582	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. <i>European Journal of Heart Failure</i> , 2015, 17, 828-836.	2.9	34
583	Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 523-526.	1.0	34
584	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1203-1213.	1.4	34
585	Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0189936.	1.1	34
586	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 939-946.	1.0	34
587	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 381-398.	1.5	34
588	Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. <i>Europace</i> , 2021, 23, 184-195.	0.7	34
589	Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3979.	1.0	34
590	Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. <i>Thrombosis and Haemostasis</i> , 2008, 100, 11-13.	1.8	33
591	Clinical outcomes of acute stroke patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 371-374.	0.6	33
592	Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. <i>PLoS ONE</i> , 2014, 9, e99276.	1.1	33
593	Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation. <i>Neurology</i> , 2015, 84, 1213-1219.	1.5	33
594	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA ₂ DS ₂ -T ₂) Be Treated With Oral Anticoagulation? A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2017, 48, 1000-1007.	1.6	33

#	ARTICLE	IF	CITATIONS
595	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1056-1063.	1.8	33
596	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. <i>Europace</i> , 2018, 20, 243-252.	0.7	33
597	Age Threshold for Ischemic Stroke Risk in Atrial Fibrillation. <i>Stroke</i> , 2018, 49, 1872-1879.	1.0	33
598	Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation. <i>Chest</i> , 2020, 157, 1266-1277.	0.4	33
599	Association between clustering of unhealthy lifestyle factors and risk of new-onset atrial fibrillation: a nationwide population-based study. <i>Scientific Reports</i> , 2020, 10, 19224.	1.6	33
600	Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. <i>JAMA Network Open</i> , 2020, 3, e203593.	2.8	33
601	Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. <i>Journal of Hypertension</i> , 1999, 17, 1203-1207.	0.3	32
602	Basic fibroblast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells. <i>European Journal of Clinical Investigation</i> , 2003, 33, 833-839.	1.7	32
603	Is hypertension a prothrombotic state?. <i>Current Hypertension Reports</i> , 2005, 7, 168-173.	1.5	32
604	Endothelial progenitor cells: what use for the cardiologist?. <i>Journal of Angiogenesis Research</i> , 2010, 2, 6.	2.9	32
605	Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants. <i>Pharmacoeconomics</i> , 2013, 31, 971-980.	1.7	32
606	Stroke and Bleeding Risk in Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2014, 44, 281.	0.7	32
607	Updated NICE guideline: management of atrial fibrillation (2014). <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1037-1040.	0.6	32
608	Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey. <i>American Journal of Medicine</i> , 2014, 127, 979-986.e2.	0.6	32
609	Statin treatment is associated with improved prognosis in patients with AF-related stroke. <i>International Journal of Cardiology</i> , 2014, 177, 129-133.	0.8	32
610	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>European Journal of Heart Failure</i> , 2015, 17, 848-874.	2.9	32
611	Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin. <i>Stroke</i> , 2016, 47, 1665-1668.	1.0	32
612	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017, 19, euw150.	0.7	32

#	ARTICLE	IF	CITATIONS
613	Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA ₂ DS ₂ -VASc score. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 37-41.	1.4	32
614	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA ₂ DS ₂ -VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2162-2170.	1.8	32
615	Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process. <i>Canadian Journal of Cardiology</i> , 2019, 35, 611-618.	0.8	32
616	Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. <i>Heart Rhythm</i> , 2020, 17, 365-371.	0.3	32
617	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. <i>European Heart Journal</i> , 2021, 42, 3541-3554.	1.0	32
618	“Novel Clinical Concepts in Thrombosis: Integrated Care for Stroke Management” Easy as ABC. <i>Thrombosis and Haemostasis</i> , 2022, 122, 316-319.	1.8	32
619	Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation. <i>Stroke</i> , 2021, 52, 3459-3468.	1.0	32
620	Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. <i>Blood Pressure</i> , 2004, 13, 183-189.	0.7	31
621	TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). <i>BMC Cardiovascular Disorders</i> , 2010, 10, 21.	0.7	31
622	Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2345-2352.	1.9	31
623	Can We Predict Stroke in Atrial Fibrillation?. <i>Clinical Cardiology</i> , 2012, 35, 21-7.	0.7	31
624	Comparación de las ecuaciones de filtrado glomerular estimado para determinar la posología de los nuevos anticoagulantes orales para pacientes con fibrilación auricular. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 497-504.	0.6	31
625	A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The Edoxaban vs. warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) study. <i>American Heart Journal</i> , 2015, 169, 597-604.e5.	1.2	31
626	Matching the NOAC to the Patient. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2282-2284.	1.2	31
627	Carotid Atherosclerosis and Stroke in Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 1643-1646.	1.0	31
628	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , 2016, 8, 309-316.	2.7	31
629	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017, 7, 41565.	1.6	31
630	Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 198, 39-45.	1.2	31

#	ARTICLE	IF	CITATIONS
631	Blood Pressure Control and Dementia Risk in Midlife Patients With Atrial Fibrillation. <i>Hypertension</i> , 2020, 75, 1296-1304.	1.3	31
632	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 92, 100-106.	1.0	31
633	ALCOHOL, HYPERTENSION, CORONARY DISEASE AND STROKE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, 189-194.	0.9	30
634	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 461-468.	0.2	30
635	Tissue inhibitor of metalloproteinase-1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension. <i>European Journal of Clinical Investigation</i> , 2005, 35, 8-12.	1.7	30
636	Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 141-143.	0.7	30
637	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018, 271, 68-74.	0.8	30
638	Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥50 years with COVID-19. <i>Journal of Arrhythmia</i> , 2021, 37, 231-237.	0.5	30
639	Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. <i>PLoS ONE</i> , 2018, 13, e0191722.	1.1	30
640	Abnormal haemorrhage, endothelial function and thrombogenesis in relation to hypertension in acute (ictus < 12 h) stroke patients: the West Birmingham Stroke Project. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 307-315.	0.5	29
641	Antiplatelet agents and anticoagulants for hypertension. <i>The Cochrane Library</i> , 2011, , CD003186.	1.5	29
642	Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation. <i>Chest</i> , 2011, 140, 918-924.	0.4	29
643	Comparison of Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 426-431.	1.0	29
644	Risk and Prediction of Sudden Cardiac Death and Ventricular Arrhythmias for Patients with Atrial Fibrillation â€” A Nationwide Cohort Study. <i>Scientific Reports</i> , 2017, 7, 46445.	1.6	29
645	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , 2017, 48, 2198-2205.	1.0	29
646	Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 879-885.	0.7	29
647	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. <i>European Heart Journal</i> , 2019, 40, 3782-3790.	1.0	29
648	Heart-type fatty acid-binding protein: an overlooked cardiac biomarker. <i>Annals of Medicine</i> , 2020, 52, 444-461.	1.5	29

#	ARTICLE	IF	CITATIONS
649	What do we do about atrial high rate episodes?. European Heart Journal Supplements, 2020, 22, O42-O52.	0.0	29
650	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. Europace, 2020, 22, 496-505.	0.7	29
651	Etiologic Workup in Cases of Cryptogenic Stroke. Stroke, 2020, 51, 1419-1427.	1.0	29
652	Endothelial function and its assessment. Expert Opinion on Investigational Drugs, 2005, 14, 1319-1336.	1.9	28
653	Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. Expert Opinion on Pharmacotherapy, 2010, 11, 685-687.	0.9	28
654	Assessment of left atrial volume: a focus on echocardiographic methods and clinical implications. Clinical Research in Cardiology, 2011, 100, 97-105.	1.5	28
655	Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. Journal of Thrombosis and Haemostasis, 2013, 11, 615-626.	1.9	28
656	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace, 2015, 17, 1215-1222.	0.7	28
657	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLAECE). European Heart Journal, 2018, 39, ehw455.	1.0	28
658	Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation. Hypertension, 2017, 70, 949-958.	1.3	28
659	Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. Clinical Research in Cardiology, 2018, 107, 772-777.	1.5	28
660	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.	1.4	28
661	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section "Special Situations. Thrombosis and Haemostasis, 2019, 119, 014-038.	1.8	28
662	Effectiveness and Safety of Oral Anticoagulants among NVAf Patients with Obesity: Insights from the ARISTOPHANES Study. Journal of Clinical Medicine, 2020, 9, 1633.	1.0	28
663	Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thrombosis Research, 2011, 127, 91-99.	0.8	27
664	Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. Clinical Research in Cardiology, 2011, 100, 531-537.	1.5	27
665	Integrating Real-Time Clinical Information to Provide Estimates of Net Clinical Benefit of Antithrombotic Therapy for Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 680-686.	0.9	27
666	Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry. PLoS ONE, 2015, 10, e0142394.	1.1	27

#	ARTICLE	IF	CITATIONS
667	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. <i>American Journal of Medicine</i> , 2018, 131, 945-955.e3.	0.6	27
668	Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 857-873.	0.6	27
669	Incidence and Risk Factors of Stroke or Systemic Embolism in Patients With Atrial Fibrillation and Heart Failure—The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 1327-1335.	0.7	27
670	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating “valvular heart disease”™ in a nationwide cohort study. <i>Europace</i> , 2019, 21, 33-40.	0.7	27
671	Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2021, 16, 1131-1140.	1.0	27
672	Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. <i>JAMA Network Open</i> , 2021, 4, e2120064.	2.8	27
673	The Effects of Implementing a Mobile Health “Technology Supported Pathway on Atrial Fibrillation”-Related Adverse Events Among Patients With Multimorbidity. <i>JAMA Network Open</i> , 2021, 4, e2140071.	2.8	27
674	Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. <i>European Journal of Internal Medicine</i> , 2022, 101, 1-7.	1.0	27
675	Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 451-459.	0.2	26
676	Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. <i>Europace</i> , 2011, 13, 145-148.	0.7	26
677	Thrombotic Complications in Heart Failure. <i>Circulation</i> , 2014, 130, 387-389.	1.6	26
678	Modern Management of Atrial Fibrillation Requires Initial Identification of “Low-Risk” Patients Using the CHA ₂ DS ₂ -VASc Score, and Not Focusing on “High-Risk” Prediction. <i>Circulation Journal</i> , 2014, 78, 1843-1845.	0.7	26
679	The Impact of Associated Diabetic Retinopathy on Stroke and Severe Bleeding Risk in Diabetic Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 147, 1103-1110.	0.4	26
680	The CHADS ₂ and CHA ₂ DS ₂ -VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. <i>International Journal of Cardiology</i> , 2015, 195, 237-242.	0.8	26
681	Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS ₂ and CHA ₂ DS ₂ -VASc scores and arrhythmia recurrences. <i>Heart</i> , 2015, 101, 126-131.	1.2	26
682	Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 184-192.	1.8	26
683	Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018, 261, 84-91.	0.8	26
684	Identification of Markers Associated With Development of Stroke in “Clinically Low-Risk” Atrial Fibrillation Patients. <i>Journal of the American Heart Association</i> , 2019, 8, e012697.	1.6	26

#	ARTICLE	IF	CITATIONS
685	Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 633-644.	0.8	26
686	Endothelial function in patients with atrial fibrillation. <i>Annals of Medicine</i> , 2020, 52, 1-11.	1.5	26
687	Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. <i>Cardiovascular Diabetology</i> , 2020, 19, 63.	2.7	26
688	Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. <i>Stroke</i> , 2021, 52, 1225-1233.	1.0	26
689	Integrated Care Systems and the Aortovascular Hub. <i>Thrombosis and Haemostasis</i> , 2022, 122, 177-180.	1.8	26
690	Incident atrial fibrillation and its risk prediction in patients developing COVID-19: A machine learning based algorithm approach. <i>European Journal of Internal Medicine</i> , 2021, 91, 53-58.	1.0	26
691	Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0125257.	1.1	26
692	Ambulatory blood pressure monitoring in heart failure: a systematic review. <i>European Journal of Heart Failure</i> , 2005, 7, 149-156.	2.9	25
693	The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 946-958.	0.8	25
694	Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. <i>Annals of Medicine</i> , 2013, 45, 274-290.	1.5	25
695	Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 1331-1337.	1.0	25
696	Laboratory Monitoring of the Non-Vitamin K Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1140-1142.	1.2	25
697	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 549-556.	1.8	25
698	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , 2015, 69, 840-845.	0.8	25
699	Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 567-574.	1.4	25
700	<sc>CHA</sc>₂<sc>DS</sc>₂<sc>â€VASC</sc> score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. <i>European Journal of Heart Failure</i> , 2016, 18, 1261-1266.	2.9	25
701	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	1.6	25
702	Epidemiology and pathogenesis of diffuse obstructive coronary artery disease: the role of arterial stiffness, shear stress, monocyte subsets and circulating microparticles. <i>Annals of Medicine</i> , 2016, 48, 444-455.	1.5	25

#	ARTICLE	IF	CITATIONS
703	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). American Journal of Cardiology, 2016, 118, 72-78.	0.7	25
704	Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. American Journal of Cardiology, 2017, 120, 1689-1695.	0.7	25
705	External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest. American Journal of Medicine, 2017, 130, 1464.e13-1464.e21.	0.6	25
706	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 626-634.	1.1	25
707	Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart and Vessels, 2018, 33, 403-412.	0.5	25
708	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study. Atherosclerosis, 2020, 312, 16-22.	0.4	25
709	Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study. Journal of Arrhythmia, 2020, 36, 668-677.	0.5	25
710	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. Internal and Emergency Medicine, 2020, 15, 1183-1192.	1.0	25
711	The Effect of Integrated Care Management on Dementia in Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 1696.	1.0	25
712	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. Cerebrovascular Diseases, 2021, 50, 326-331.	0.8	25
713	Integrated care and outcomes in patients with atrial fibrillation and comorbidities. European Journal of Clinical Investigation, 2021, 51, e13498.	1.7	25
714	Association between exercise habits and stroke, heart failure, and mortality in Korean patients with incident atrial fibrillation: A nationwide population-based cohort study. PLoS Medicine, 2021, 18, e1003659.	3.9	25
715	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clinical Research in Cardiology, 2022, 111, 70-84.	1.5	25
716	Metabolically healthy obesity and cardiovascular events: A nationwide cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 2492-2501.	2.2	25
717	Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagulation and Fibrinolysis, 2002, 13, 35-41.	0.5	24
718	Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?. European Journal of Clinical Investigation, 2004, 34, 9-13.	1.7	24
719	Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scandinavian Cardiovascular Journal, 2010, 44, 92-99.	0.4	24
720	Current practice in Europe: how do we manage patients with ventricular tachycardia? European Heart Rhythm Association survey. Europace, 2013, 15, 167-169.	0.7	24

#	ARTICLE	IF	CITATIONS
721	Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin. <i>British Journal of Haematology</i> , 2014, 166, 571-580.	1.2	24
722	Overtreatment and Undertreatment With Anticoagulation in Relation to Cardioversion of Atrial Fibrillation (the RHYTHM-AF Study). <i>American Journal of Cardiology</i> , 2014, 113, 480-484.	0.7	24
723	Benefit of Anticoagulation Therapy in Hyperthyroidism-Related Atrial Fibrillation. <i>Clinical Cardiology</i> , 2015, 38, 476-482.	0.7	24
724	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1051-1062.	1.0	24
725	Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study. <i>Clinical Research in Cardiology</i> , 2017, 106, 202-210.	1.5	24
726	Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 701-710.	1.3	24
727	Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2019, 8, 2228.	1.0	24
728	Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23104.	0.9	24
729	Hypertension management in cardio-oncology. <i>Journal of Human Hypertension</i> , 2020, 34, 673-681.	1.0	24
730	Association of enlarged perivascular spaces and anticoagulant-related intracranial hemorrhage. <i>Neurology</i> , 2020, 95, e2192-e2199.	1.5	24
731	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2455-2463.	1.1	24
732	Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1234.	1.0	24
733	Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 415-423.	1.4	24
734	Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: comparing common clinical risk scores and machine learning algorithms. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 548-556.	1.8	24
735	Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons. <i>PLoS ONE</i> , 2014, 9, e100478.	1.1	24
736	Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 109703-109711.	0.8	24
737	Heart failure-the importance of ethnicity. <i>European Journal of Heart Failure</i> , 2004, 6, 831-843.	2.9	23
738	Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?. <i>European Heart Journal</i> , 2007, 28, 929-940.	1.0	23

#	ARTICLE	IF	CITATIONS
739	Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS ₂ and CHA ₂ DS ₂ -VASc Scores in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 31-38.	2.1	23
740	Hospital delay in South Asian patients with acute ST-elevation myocardial infarction in the UK. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 737-742.	0.8	23
741	Warfarin or novel oral anticoagulants for atrial fibrillation?. <i>Lancet, The</i> , 2014, 383, 931-933.	6.3	23
742	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 7-20.	1.0	23
743	Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. <i>Scientific Reports</i> , 2016, 6, 31755.	1.6	23
744	Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1247.e23-1247.e28.	0.8	23
745	Predicting Unsuccessful Electrical Cardioversion for Acute Atrial Fibrillation (from the AF-CVS) Tj ETQq1 1 0.784314rgBT /Overlock 10 T	0.7	23
746	Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation. <i>Europace</i> , 2017, 19, 1944-1950.	0.7	23
747	Coronary artery disease and risk of adverse cardiac events and stroke. <i>European Journal of Clinical Investigation</i> , 2017, 47, 819-828.	1.7	23
748	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-CAF General Pilot Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 566-572.	0.8	23
749	Use of the SAME-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. <i>Heart Rhythm</i> , 2018, 15, 615-623.	0.3	23
750	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	1.4	23
751	Atrial Fibrillation and Stroke. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 243-255.	0.7	23
752	Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study. <i>BMJ Open</i> , 2021, 11, e048839.	0.8	23
753	Biomarkers for Atrial Fibrillation Detection After Stroke. <i>Neurology</i> , 2021, 97, e1775-e1789.	1.5	23
754	Stroke prevention in Atrial Fibrillation. <i>European Heart Journal</i> , 2017, 38, 4-5.	1.0	23
755	Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2020, 22, I13-I21.	0.0	23
756	Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 441-450.	0.6	22

#	ARTICLE	IF	CITATIONS
757	Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers. <i>Prostate</i> , 2011, 71, 1047-1053.	1.2	22
758	Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	22
759	Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial. <i>International Journal of Cardiology</i> , 2016, 221, 379-382.	0.8	22
760	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E12-22.	0.7	22
761	Impact of aerobic fitness on cerebral blood flow and cerebral vascular responsiveness to CO ₂ in young and older men. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2017, 27, 634-642.	1.3	22
762	Enhancing the "real world" prediction of cardiovascular events and major bleeding with the CHA ₂ DS ₂ -VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018, 50, 26-34.	1.5	22
763	A U-shaped relationship of body mass index on atrial fibrillation recurrence post ablation: A report from the Guangzhou atrial fibrillation ablation registry. <i>EBioMedicine</i> , 2018, 35, 40-45.	2.7	22
764	Reassessment of Risk for Stroke During Follow-up of Patients With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2019, 170, 663.	2.0	22
765	Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. <i>PLoS ONE</i> , 2019, 14, e0209593.	1.1	22
766	Hypertension Burden and the Risk of New-Onset Atrial Fibrillation. <i>Hypertension</i> , 2021, 77, 919-928.	1.3	22
767	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. <i>BMC Medicine</i> , 2021, 19, 139.	2.3	22
768	Atrial fibrillation in low- and middle-income countries: a narrative review. <i>European Heart Journal Supplements</i> , 2020, 22, O61-O77.	0.0	22
769	Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry. <i>Medical Science Monitor</i> , 2019, 25, 2649-2657.	0.5	22
770	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	2.3	22
771	Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2193-2207.	0.9	21
772	Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 43-53.	1.5	21
773	Bare-Metal vs. Drug-Eluting Stents in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 2674-2681.	0.7	21
774	Relation of the SAME-TT 2 R 2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2016, 216, 168-172.	0.8	21

#	ARTICLE	IF	CITATIONS
775	Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. <i>American Journal of Medicine</i> , 2016, 129, 1110-1116.	0.6	21
776	Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 535-544.	1.0	21
777	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. <i>Circulation Journal</i> , 2016, 80, 2102-2108.	0.7	21
778	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018, 40, 114-122.	1.1	21
779	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 255, 69-73.	0.8	21
780	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , 2018, 15, e37-e60.	0.3	21
781	Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort. <i>American Journal of Cardiology</i> , 2018, 121, 437-444.	0.7	21
782	Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 91.	0.7	21
783	Prevalence of Hypertension in the Middle Belt of Ghana: A Community-Based Screening Study. <i>International Journal of Hypertension</i> , 2019, 2019, 1-7.	0.5	21
784	Elevated blood plasma levels of tissue factor-bearing extracellular vesicles in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2019, 173, 141-150.	0.8	21
785	Relation of the CHA2DS2-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study). <i>American Journal of Cardiology</i> , 2019, 123, 402-408.	0.7	21
786	Population-Based Screening or Targeted Screening Based on Initial Clinical Risk Assessment for Atrial Fibrillation: A Report from the Huawei Heart Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1493.	1.0	21
787	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006058.	0.9	21
788	Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1698.	1.0	21
789	Cardiac rehabilitation and all-cause mortality in patients with heart failure: a retrospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1704-1710.	0.8	21
790	Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (≥85 years) Patients With Newly Diagnosed Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2021, 96, 52-65.	1.4	21
791	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021, 85, 80-85.	1.0	21
792	Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metaanalysis. <i>European Journal of Internal Medicine</i> , 2021, 85, 27-33.	1.0	21

#	ARTICLE	IF	CITATIONS
793	Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. <i>Diabetes Care</i> , 2021, 44, 1393-1401.	4.3	21
794	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. <i>Europace</i> , 2021, 23, 1511-1527.	0.7	21
795	Comparative Effectiveness of Early Rhythm Control Versus Rate Control for Cardiovascular Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e023055.	1.6	21
796	More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, Tj ETQq0 0 0 rgt /Overlock 10 Tf		
797	Atrial fibrillation post-myocardial infarction: Frequency, consequences, and management. <i>Current Heart Failure Reports</i> , 2004, 1, 149-155.	1.3	20
798	The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease. <i>Diabetic Medicine</i> , 2005, 22, 249-255.	1.2	20
799	Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 521-530.	1.0	20
800	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. <i>Europace</i> , 2015, 17, 507-508.	0.7	20
801	Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. <i>Europace</i> , 2019, 21, 1297-1306.	0.7	20
802	Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). <i>American Journal of Cardiology</i> , 2020, 125, 48-54.	0.7	20
803	Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 975-986.	1.3	20
804	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016239.	1.6	20
805	High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 78.	2.7	20
806	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021, 16, 1231-1237.	1.0	20
807	Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population-based cohort study. <i>Clinical Cardiology</i> , 2021, 44, 1602-1612.	0.7	20
808	Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants. <i>Stroke</i> , 2021, 52, 3132-3141.	1.0	20
809	4S-ABC scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13751.	1.7	20
810	The endothelium, inflammation, and coagulation in sepsis. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 20-22.	2.3	19

#	ARTICLE	IF	CITATIONS
811	Circulating levels of adiponectin, leptin, and tumour necrosis factor $\hat{\pm}$ in hypertension. <i>Annals of Medicine</i> , 2009, 41, 291-300.	1.5	19
812	Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting. <i>Chest</i> , 2009, 135, 983-990.	0.4	19
813	Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation. <i>Europace</i> , 2012, 14, 741-744.	0.7	19
814	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E864-70.	0.7	19
815	Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 1526-1532.	0.7	19
816	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 610-617.	0.9	19
817	Comparative Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 146-153.	1.5	19
818	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. <i>American Heart Journal</i> , 2017, 190, 86-93.	1.2	19
819	Variations of Prevalence and Incidence of Atrial Fibrillation and Oral Anticoagulation Rate According to Different Analysis Approaches. <i>Scientific Reports</i> , 2018, 8, 6856.	1.6	19
820	Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. <i>Clinical Cardiology</i> , 2018, 41, 744-751.	0.7	19
821	Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. <i>Stroke</i> , 2019, 50, 1480-1489.	1.0	19
822	Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2019, 292, 126-130.	0.8	19
823	Effect of small-vessel disease on cognitive trajectory after atrial fibrillation-related ischaemic stroke or $\hat{\pm}$ IA. <i>Journal of Neurology</i> , 2019, 266, 1250-1259.	1.8	19
824	Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 964-972.	0.8	19
825	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 508-515.	1.1	19
826	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. <i>American Journal of Cardiology</i> , 2020, 125, 383-391.	0.7	19
827	Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIA Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e013789.	1.6	19
828	Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population. <i>Stroke</i> , 2020, 51, 1772-1780.	1.0	19

#	ARTICLE	IF	CITATIONS
829	Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1286.	1.0	19
830	Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 24.	2.7	19
831	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding. <i>Stroke</i> , 2021, 52, 511-520.	1.0	19
832	Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. <i>Journal of Arrhythmia</i> , 2021, 37, 990-1006.	0.5	19
833	Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199735.	1.4	19
834	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants. <i>Journal of Atrial Fibrillation</i> , 2013, 6, 783.	0.5	19
835	Mobile health technology in atrial fibrillation. <i>Expert Review of Medical Devices</i> , 2022, 19, 327-340.	1.4	19
836	Platelet activation in the hypertensive disorders of pregnancy. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 523-529.	1.9	18
837	An 8-year follow-up study of acute admissions with heart failure in a multiethnic population. <i>European Journal of Heart Failure</i> , 2004, 6, 669-672.	2.9	18
838	Assessment of endothelial (dys)function in atrial fibrillation. <i>Annals of Medicine</i> , 2009, 41, 576-590.	1.5	18
839	Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. <i>European Journal of Heart Failure</i> , 2011, 13, 489-495.	2.9	18
840	Peri-operative management of ophthalmic patients taking antithrombotic therapy. <i>International Journal of Clinical Practice</i> , 2011, 65, 361-371.	0.8	18
841	Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye: Table 1. <i>British Journal of Ophthalmology</i> , 2014, 98, 1141-1143.	2.1	18
842	Net clinical benefit of edoxaban versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , 2015, 201, 693-698.	0.8	18
843	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 315-336.	2.3	18
844	Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). <i>American Heart Journal</i> , 2015, 169, 464-471.e2.	1.2	18
845	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016, 102, 1878-1882.	1.2	18
846	Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	18

#	ARTICLE	IF	CITATIONS
847	Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA ₂ DS ₂ -VASc Score of 1 (Men) or 2 (Women)? Journal of the American Heart Association, 2016, 5, .	1.6	18
848	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. Journal of the American Heart Association, 2016, 5, .	1.6	18
849	The SAME-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.	0.6	18
850	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. EBioMedicine, 2017, 18, 199-203.	2.7	18
851	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. European Journal of Internal Medicine, 2018, 54, 34-39.	1.0	18
852	Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. American Heart Journal, 2019, 218, 123-127.	1.2	18
853	“Real-world” observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	0.7	18
854	Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 405-414.	1.4	18
855	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. Frontiers in Medicine, 2020, 7, 54.	1.2	18
856	Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. Annals of Medicine, 2021, 53, 17-25.	1.5	18
857	Peripheral Arterial Disease in Patients with Atrial Fibrillation: The AFFIRM Study. American Journal of Medicine, 2021, 134, 514-518.	0.6	18
858	Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 50-58.	1.4	18
859	Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. Stroke, 2021, 52, 521-530.	1.0	18
860	Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thrombosis Research, 2021, 205, 1-7.	0.8	18
861	Exercise-Based Cardiac Rehabilitation and All-Cause Mortality Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e020804.	1.6	18
862	Revisiting the dynamic risk profile of cardiovascular/non-cardiovascular multimorbidity in incident atrial fibrillation patients and five cardiovascular/non-cardiovascular outcomes: A machine learning approach. Journal of Arrhythmia, 2021, 37, 931-941.	0.5	18
863	The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2021, 10, 65-67.	1.3	18
864	Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 169-176.	1.8	18

#	ARTICLE	IF	CITATIONS
865	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
866	Effects of Radiofrequency Catheter Ablation of Atrial Fibrillation on Soluble P-Selectin, Von Willebrand Factor and IL-6 in the Peripheral and Cardiac Circulation. <i>PLoS ONE</i> , 2014, 9, e111760.	1.1	18
867	Exercise-based cardiac rehabilitation vs. percutaneous coronary intervention for chronic coronary syndrome: impact on morbidity and mortality. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1074-1080.	0.8	18
868	Association of rhythm control with incident dementia among patients with atrial fibrillation: a nationwide population-based cohort study. <i>Age and Ageing</i> , 2022, 51, .	0.7	18
869	Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial. <i>International Journal of Stroke</i> , 2022, 17, 583-589.	2.9	18
870	Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. <i>Stroke</i> , 2022, 53, 1873-1882.	1.0	18
871	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. , 2000, , CD003333.		17
872	Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. <i>Blood Pressure</i> , 2005, 14, 38-44.	0.7	17
873	Assessment of endothelial dysfunction. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 557-571.	0.6	17
874	Hormone Replacement Therapy and Adverse Outcomes in Women With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3076-3079.	1.0	17
875	Non-Vitamin K Antagonist Oral Anticoagulants. <i>Chest</i> , 2014, 145, 1177-1178.	0.4	17
876	Influence of age on respiratory modulation of muscle sympathetic nerve activity, blood pressure and baroreflex function in humans. <i>Experimental Physiology</i> , 2015, 100, 1039-1051.	0.9	17
877	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. <i>International Journal of Clinical Practice</i> , 2015, 69, 1341-1348.	0.8	17
878	Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 497-504.	0.4	17
879	Atrial Fibrillation Patients Categorized as "Not for Anticoagulation" According to the 2014 Canadian Cardiovascular Society Algorithm Are Not "Low Risk". <i>Canadian Journal of Cardiology</i> , 2015, 31, 24-28.	0.8	17
880	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017, 34, 2043-2057.	1.3	17
881	Sex-Related Differences in the Clinical Events of Patients With Atrial Fibrillation—The Fushimi AF Registry. <i>Circulation Journal</i> , 2017, 81, 1403-1410.	0.7	17
882	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIA Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 279-287.	1.8	17

#	ARTICLE	IF	CITATIONS
883	Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 341-348.	0.6	17
884	Improvement and Aggravation of Spontaneous Unruptured Vertebral Artery Dissection. <i>Cerebrovascular Diseases Extra</i> , 2018, 7, 153-164.	0.5	17
885	Stroke Risk Stratification for Atrial Fibrillation Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2409-2411.	1.2	17
886	Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey. <i>TH Open</i> , 2018, 02, e233-e241.	0.7	17
887	Acute hydrocortisone administration reduces cardiovascular baroreflex sensitivity and heart rate variability in young men. <i>Journal of Physiology</i> , 2018, 596, 4847-4861.	1.3	17
888	Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006990.	2.1	17
889	Cognitive Impairment Before Atrial Fibrillation-Related Ischemic Events: Neuroimaging and Prognostic Associations. <i>Journal of the American Heart Association</i> , 2020, 9, e014537.	1.6	17
890	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005894.	0.9	17
891	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. <i>American Journal of Medicine</i> , 2020, 133, e269-e279.	0.6	17
892	Heart rate variability in patients with atrial fibrillation and hypertension. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13361.	1.7	17
893	Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. <i>Scientific Reports</i> , 2021, 11, 3737.	1.6	17
894	Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 805-814.	0.9	17
895	Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, 111, 23-33.	1.5	17
896	Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 871-877.	0.3	17
897	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. <i>European Heart Journal Supplements</i> , 2020, 22, O14-O27.	0.0	17
898	Atrial High-Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e022487.	1.6	17
899	Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 841-855.	1.9	16
900	Stroke prevention in AF. <i>Nature Reviews Cardiology</i> , 2012, 9, 71-73.	6.1	16

#	ARTICLE	IF	CITATIONS
901	Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation. PLoS ONE, 2015, 10, e0145579.	1.1	16
902	Atrial Fibrillation in Patients With Hypertension. Hypertension, 2016, 68, 544-545.	1.3	16
903	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace, 2017, 19, 1630-1636.	0.7	16
904	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.	1.6	16
905	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillationâ€”The Fushimi AF Registry â€”. Circulation Journal, 2018, 82, 2983-2991.	0.7	16
906	Heart Failure and Stroke. Current Heart Failure Reports, 2018, 15, 287-296.	1.3	16
907	Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials. International Journal of Stroke, 2019, 14, 856-861.	2.9	16
908	Safety of direct oral anticoagulants in realâ€”world clinical practice: translating the trials to everyday clinical management. Expert Opinion on Drug Safety, 2019, 18, 187-209.	1.0	16
909	Atrial Fibrillation Increases the Risk of Early-Onset Dementia in the General Population: Data from a Population-Based Cohort. Journal of Clinical Medicine, 2020, 9, 3665.	1.0	16
910	The counterintuitive role of exercise in the prevention and cause of atrial fibrillation. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H1051-H1058.	1.5	16
911	The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms. Journal of Clinical Epidemiology, 2020, 125, 100-107.	2.4	16
912	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 229-237.	1.8	16
913	Acute ischemic stroke management: concepts and controversies.A narrative review. Expert Review of Neurotherapeutics, 2021, 21, 65-79.	1.4	16
914	Relationship between multimorbidity and outcomes in atrial fibrillation. Experimental Gerontology, 2021, 153, 111482.	1.2	16
915	The Association of CHA2DS2-VASc Score and Blood Biomarkers with Ischemic Stroke Outcomes: The Belgrade Stroke Study. PLoS ONE, 2014, 9, e106439.	1.1	16
916	Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation. Stroke, 2022, 53, 497-504.	1.0	16
917	The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	16
918	A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. Journal of Internal Medicine, 2000, 248, 316-318.	2.7	15

#	ARTICLE	IF	CITATIONS
919	Platelets, atherosclerosis and the endothelium: new therapeutic targets?. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1765-1776.	1.9	15
920	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". <i>Thrombosis and Haemostasis</i> , 2009, 102, 914-915.	1.8	15
921	Vernakalant hydrochloride for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1929-1937.	1.9	15
922	Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 703-713.	0.6	15
923	Endothelium-dependent and endothelium-independent vasodilatation of the cutaneous circulation in sickle cell disease. <i>European Journal of Clinical Investigation</i> , 2011, 41, 546-551.	1.7	15
924	An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. <i>Chest</i> , 2011, 139, 1402-1409.	0.4	15
925	Prevention of Venous Thromboembolism with New Oral Anticoagulants versus Standard Pharmacological Treatment in Acute Medically Ill Patients. <i>Drugs</i> , 2012, 72, 1755-1764.	4.9	15
926	Comparison of Frequency of Major Adverse Events in Patients With Atrial Fibrillation Receiving Bare-Metal Versus Drug-Eluting Stents in Their Coronary Arteries. <i>American Journal of Cardiology</i> , 2012, 110, 7-12.	0.7	15
927	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1619-1629.	0.6	15
928	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>PLoS ONE</i> , 2014, 9, e113447.	1.1	15
929	Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 403-409.	1.8	15
930	Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 209, 1-6.	0.8	15
931	Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. <i>International Journal of Stroke</i> , 2017, 12, 222-228.	2.9	15
932	Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 328-334.	0.8	15
933	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. <i>International Journal of Cardiology</i> , 2018, 260, 93-98.	0.8	15
934	Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. <i>Europace</i> , 2018, 20, 1382-1387.	0.7	15
935	Sex differences in risk of incident venous thromboembolism in heart failure patients. <i>Clinical Research in Cardiology</i> , 2019, 108, 101-109.	1.5	15
936	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , 2019, 21, 1633-1638.	0.7	15

#	ARTICLE	IF	CITATIONS
937	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. <i>Scientific Reports</i> , 2019, 9, 6690.	1.6	15
938	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , 2019, 108, 1034-1041.	1.5	15
939	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Heart Rhythm</i> , 2020, 17, e269-e316.	0.3	15
940	Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. <i>American Journal of Medicine</i> , 2020, 133, 1328-1335.	0.6	15
941	Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. <i>Europace</i> , 2021, 23, 937-947.	0.7	15
942	Exercise and the Risk of Dementia in Patients with Newly Diagnosed Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3126.	1.0	15
943	Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. <i>Biomedicines</i> , 2021, 9, 843.	1.4	15
944	Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 778-786.	1.8	15
945	Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. <i>Internal and Emergency Medicine</i> , 2022, 17, 1001-1012.	1.0	15
946	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 560-573.	1.5	15
947	Radiofrequency catheter ablation of atrial fibrillation: A review of techniques. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 405-415.	2.3	15
948	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
949	Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 125-131.	1.0	14
950	Performing Repeated Noninvasive Bedside Measures of Volume Response to Intravenous Furosemide in Acute Pulmonary Edema: A Feasibility Assessment. <i>Cardiovascular Therapeutics</i> , 2009, 27, 89-95.	1.1	14
951	Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 131-140.	0.9	14
952	Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 613-621.	0.2	14
953	Assessing Bleeding Risk With the <sc>HAS-BLED</sc> Score: Balancing Simplicity, Practicality, and Predictive Value in Bleeding-Risk Assessment. <i>Clinical Cardiology</i> , 2015, 38, 562-564.	0.7	14
954	Improved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosis in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e012241.	0.8	14

#	ARTICLE	IF	CITATIONS
955	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. <i>Advances in Therapy</i> , 2017, 34, 357-377.	1.3	14
956	Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin â€“ Warfarin in Patients Undergoing Cardioversion) <i>Tj ETQq0 0 OrgBT /Overlock 10 T</i>		
957	Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 18-23.	1.0	14
958	Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. <i>BMJ Open</i> , 2018, 8, e020191.	0.8	14
959	Determinants of lowâ€quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020, 190, 588-593.	1.2	14
960	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f101-f110.	1.4	14
961	Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. <i>Cardiovascular Diabetology</i> , 2021, 20, 128.	2.7	14
962	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2022, 196, 70-78.	1.2	14
963	Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study. <i>Medical Science Monitor</i> , 2019, 25, 8011-8018.	0.5	14
964	Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2020, 50, 267.	0.7	14
965	Early Rhythm Control and the Risks of Ischemic Stroke, Heart Failure, Mortality, and Adverse Events When Performed Early (<3 Months): A Nationwide Cohort Study of Newly Diagnosed Patients with Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1899-1910.	1.8	14
966	Malignant Hypertension: Current Perspectives and Challenges. <i>Journal of the American Heart Association</i> , 2022, 11, e023397.	1.6	14
967	Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2007, 261, 577-586.	2.7	13
968	New approaches to therapy with omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2008, 10, 79-87.	2.0	13
969	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2009, 132, 227-232.	0.8	13
970	Fondaparinux: an overview. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 577-585.	0.6	13
971	Renin-angiotensin blockade in diabetic retinopathy. <i>International Journal of Clinical Practice</i> , 2011, 65, 113-116.	0.8	13
972	Atrial fibrillation and stroke prevention: brief observations on the last decade. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 403-406.	0.6	13

#	ARTICLE	IF	CITATIONS
973	Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 166-177.	1.5	13
974	Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 3202-3207.	1.0	13
975	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2016, 279, 467-476.	2.7	13
976	Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2017, 19, euw107.	0.7	13
977	Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of "valvular" atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1593-1598.	0.7	13
978	Adding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 220-223.	1.6	13
979	Persistency of left atrial linear lesions after radiofrequency catheter ablation for atrial fibrillation: Data from an invasive follow-up electrophysiology study. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1403-1414.	0.8	13
980	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. <i>American Journal of Hypertension</i> , 2017, 30, 1063-1065.	1.0	13
981	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 200, 32-36.	1.2	13
982	Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project. <i>International Journal of Clinical Practice</i> , 2018, 72, e13247.	0.8	13
983	Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1561-1567.	0.7	13
984	Renal function and outcomes after catheter ablation of patients with atrial fibrillation: The Guangzhou atrial fibrillation ablation registry. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 420-429.	0.7	13
985	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	1.2	13
986	One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. <i>International Journal of Cardiology</i> , 2019, 274, 158-162.	0.8	13
987	Stroke prevention in atrial fibrillation: State of the art. <i>International Journal of Cardiology</i> , 2019, 287, 201-209.	0.8	13
988	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1000-1008.	0.7	13
989	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.	0.8	13
990	Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f3-f10.	1.4	13

#	ARTICLE	IF	CITATIONS
991	The impact of atrial fibrillation and long-term oral anticoagulant use on all-cause and cardiovascular mortality: A 12-year evaluation of the prospective Brazilian Study of Stroke Mortality and Morbidity. <i>International Journal of Stroke</i> , 2022, 17, 48-58.	2.9	13
992	Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 71.	2.7	13
993	Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. <i>Pharmacological Research</i> , 2021, 167, 105534.	3.1	13
994	Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. <i>Journal of Clinical Medicine</i> , 2021, 10, 2238.	1.0	13
995	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. <i>Europace</i> , 2022, 24, 375-383.	0.7	13
996	Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 2602-2605.	2.9	13
997	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
998	A comprehensive insight of novel antioxidant therapies for atrial fibrillation management. <i>Drug Metabolism Reviews</i> , 2015, 47, 388-400.	1.5	13
999	Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data. <i>Journal of the American Heart Association</i> , 2021, 10, e021970.	1.6	13
1000	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	2.1	13
1001	Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. <i>European Journal of Internal Medicine</i> , 2022, 103, 84-94.	1.0	13
1002	Platelet adhesion in hypertension: Application of a novel assay of platelet adhesion. <i>Annals of Medicine</i> , 2005, 37, 55-60.	1.5	12
1003	The 2010 European Society of Cardiology Guidelines on the Management of Atrial Fibrillation. <i>Chest</i> , 2011, 139, 738-741.	0.4	12
1004	Anticoagulation versus placebo for heart failure in sinus rhythm. , 2012, , CD003336.		12
1005	Î2-Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. <i>Chest</i> , 2013, 144, 1564-1570.	0.4	12
1006	Stroke Prevention in Asian Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 1608-1609.	1.0	12
1007	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1101-1114.	0.9	12
1008	Relationship of troponin to incident atrial fibrillation occurrence, recurrence after radiofrequency ablation and prognosis: a systematic review, meta-analysis and meta-regression. <i>Biomarkers</i> , 2018, 23, 512-517.	0.9	12

#	ARTICLE	IF	CITATIONS
1009	Impact of Monocyte platelet aggregates on human coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12911.	1.7	12
1010	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , 2018, 50, 511-518.	1.5	12
1011	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792.	0.7	12
1012	Assessment of Arterial Stiffness in Patients With Resistant Hypertension: Additional Insights Into the Pathophysiology of This Condition?. <i>American Journal of Hypertension</i> , 2020, 33, 107-115.	1.0	12
1013	Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: A report from the China atrial fibrillation registry study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2759-2767.	0.8	12
1014	Malignant hypertension: does this still exist?. <i>Journal of Human Hypertension</i> , 2020, 34, 1-4.	1.0	12
1015	Cerebrovascular Dysfunction in Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2020, 11, 1066.	1.3	12
1016	<p>⚠Cardiac Electronic Devices: Future Directions and Challenges⚠. <i>Medical Devices: Evidence and Research</i> , 2020, Volume 13, 325-338.	0.4	12
1017	Role for machine learning in sex-specific prediction of successful electrical cardioversion in atrial fibrillation?. <i>Open Heart</i> , 2020, 7, e001297.	0.9	12
1018	Age-Dependent Anticoagulant Therapy for Atrial Fibrillation Patients with Intermediate Risk of Ischemic Stroke: A Nationwide Population-Based Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1151-1160.	1.8	12
1019	Excessive Supraventricular Ectopic Activity and Adverse Cardiovascular Outcomes: a Systematic Review and Meta-analysis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 14.	2.0	12
1020	Longer term stroke risk in intracerebral haemorrhage survivors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 840-845.	0.9	12
1021	Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1282-1292.	2.3	12
1022	Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. <i>Europace</i> , 2021, 23, 1369-1379.	0.7	12
1023	Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2021, 36, 793-812.	2.5	12
1024	Associations of hypertension burden on subsequent dementia: a population-based cohort study. <i>Scientific Reports</i> , 2021, 11, 12291.	1.6	12
1025	Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 588-595.	1.8	12
1026	Stroke prevention in atrial fibrillation: comparison of recent international guidelines. <i>European Heart Journal Supplements</i> , 2020, 22, O53-O60.	0.0	12

#	ARTICLE	IF	CITATIONS
1027	Adherence to the ABC (Atrial fibrillation Better Care) pathway in the Balkan region: the BALKAN-AF survey. Polish Archives of Internal Medicine, 2020, 130, 187-195.	0.3	12
1028	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. Europace, 2022, 24, 721-728.	0.7	12
1029	Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation. European Heart Journal Supplements, 2022, 24, A42-A55.	0.0	12
1030	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry. Journal of the American Heart Association, 2022, 11, e023907.	1.6	12
1031	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. Clinical Research in Cardiology, 2022, 111, 548-559.	1.5	12
1032	A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. European Heart Journal, 2022, 43, 2916-2918.	1.0	12
1033	Serum urate is associated with baseline renal dysfunction but not survival or deterioration in renal function in malignant phase hypertension. Journal of Hypertension, 2000, 18, 97-101.	0.3	11
1034	Tedisamil: a new novel antiarrhythmic. Expert Opinion on Investigational Drugs, 2004, 13, 151-160.	1.9	11
1035	The new NICE guideline on atrial fibrillation management. Heart, 2007, 93, 23-23.	1.2	11
1036	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurology, The, 2010, 9, 1140-1142.	4.9	11
1037	Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy. Thrombosis and Haemostasis, 2013, 110, 623-625.	1.8	11
1038	Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer. British Journal of Cancer, 2014, 111, 1742-1749.	2.9	11
1039	Specific risk scores for specific purposes: Use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation. Thrombosis Research, 2014, 134, 217-218.	0.8	11
1040	Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation. Stroke, 2014, 45, 2127-2130.	1.0	11
1041	A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial. Journal of Thrombosis and Haemostasis, 2015, 13, 1405-1413.	1.9	11
1042	Stroke in atrial fibrillation and improving the identification of "high-risk" patients: the crossroads of immunity and thrombosis. Journal of Thrombosis and Haemostasis, 2015, 13, 1968-1970.	1.9	11
1043	Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure. Stroke, 2015, 46, 608-609.	1.0	11
1044	Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. PLoS ONE, 2016, 11, e0157129.	1.1	11

#	ARTICLE	IF	CITATIONS
1045	Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the "Real World" Gastroenterology, 2017, 152, 932-934.	0.6	11
1046	Editors' Choice 2016 papers in Thrombosis and Haemostasis. Thrombosis and Haemostasis, 2017, 117, 204-206.	1.8	11
1047	Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study. ESC Heart Failure, 2018, 5, 319-326.	1.4	11
1048	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation" the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. Europace, 2018, 20, 253-262.	0.7	11
1049	Disease progression after ablation for atrial flutter compared with atrial fibrillation: A nationwide cohort study. International Journal of Clinical Practice, 2018, 72, e13258.	0.8	11
1050	Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. Journal of Clinical Medicine, 2019, 8, 1624.	1.0	11
1051	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. International Journal of Clinical Practice, 2019, 73, e13285.	0.8	11
1052	Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. American Heart Journal, 2020, 229, 81-91.	1.2	11
1053	Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding: A nationwide cohort study. Heart Rhythm, 2020, 17, 1745-1751.	0.3	11
1054	Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry. Journal of Arrhythmia, 2020, 36, 408-416.	0.5	11
1055	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. Journal of Clinical Medicine, 2020, 9, 1969.	1.0	11
1056	Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. Medical Science Monitor, 2019, 25, 4691-4698.	0.5	11
1057	MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage. International Journal of Stroke, 2023, 18, 85-94.	2.9	11
1058	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute Cardiovascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	0.7	11
1059	Low Risk of Dementia in Patients With Newly Diagnosed Atrial Fibrillation and a Clustering of Healthy Lifestyle Behaviors: A Nationwide Population-Based Cohort Study. Journal of the American Heart Association, 2022, 11, e023739.	1.6	11
1060	Interactive Remote Patient Monitoring Devices for Managing Chronic Health Conditions: Systematic Review and Meta-analysis. Journal of Medical Internet Research, 2022, 24, e35508.	2.1	11
1061	Association between exercise habit changes and mortality following a cardiovascular event. Heart, 2022, 108, 1945-1951.	1.2	11
1062	Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs?. American Journal of Hypertension, 2000, 13, 934-939.	1.0	10

#	ARTICLE	IF	CITATIONS
1063	Management of Hypertension in Pregnancy. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 253-262.	1.0	10
1064	Congestive Heart Failure and Virchow's Triad: A Neglected Association. <i>Wiener Medizinische Wochenschrift</i> , 2003, 153, 411-416.	0.5	10
1065	Burden of atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2009, 25, 1261-1263.	0.9	10
1066	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. <i>Annals of Medicine</i> , 2010, 42, 562-575.	1.5	10
1067	The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. <i>Cardiovascular Therapeutics</i> , 2011, 29, e12-e22.	1.1	10
1068	Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1057-1064.	1.9	10
1069	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 77-90.	0.6	10
1070	Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism. <i>Heart</i> , 2016, 102, 975-983.	1.2	10
1071	Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 2980-2982.	1.0	10
1072	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , 2018, 50, 288-302.	1.5	10
1073	Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2018, 252, 96-100.	0.8	10
1074	Age-Dependent Prognostic Impact of Paroxysmal Versus Sustained Atrial Fibrillation on the Incidence of Cardiac Death and Heart Failure Hospitalization (the Fushimi AF Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1420-1429.	0.7	10
1075	Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. <i>Europace</i> , 2019, 22, 47-57.	0.7	10
1076	Time-dependent prediction of arrhythmia recurrences during long-term follow-up in patients undergoing catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry. <i>Scientific Reports</i> , 2019, 9, 7112.	1.6	10
1077	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	0.7	10
1078	Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 283.	0.7	10
1079	Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). <i>American Journal of Cardiology</i> , 2019, 123, 592-597.	0.7	10
1080	Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1808-1810.	1.2	10

#	ARTICLE	IF	CITATIONS
1081	Cardiovascular Events and Mortality in Patients With Atrial Fibrillation and Anemia (from the Fushimi) Tj ETQq1 1 0,784314 rgBT /Ove	0.7	10
1082	Feasibility of weight loss in obese atrial fibrillation patients attending a specialist arrhythmia clinic and its impact on ablation outcomes. <i>Journal of Arrhythmia</i> , 2020, 36, 984-990.	0.5	10
1083	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 1617-1619.	1.0	10
1084	Temporal Trends of Emergency Department Visits of Patients with Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1485.	1.0	10
1085	Association of relative wall thickness of left ventricle with incidence of thromboembolism in patients with non-valvular atrial fibrillation: The Fushimi AF Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 273-283.	1.8	10
1086	Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: A report from the Chinese Atrial Fibrillation Registry study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 333-341.	0.8	10
1087	Understanding the global burden of atrial fibrillation and regional variations: we need improvement. <i>Cardiovascular Research</i> , 2021, 117, 1420-1422.	1.8	10
1088	Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13385.	1.7	10
1089	Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage. <i>Neurology</i> , 2021, 96, e1954-e1965.	1.5	10
1090	Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the C ₂ HEST Score: The West Birmingham Atrial Fibrillation Project. <i>Journal of the American Heart Association</i> , 2021, 10, e017519.	1.6	10
1091	Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 679-689.	1.3	10
1092	Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. <i>Cardiovascular Diabetology</i> , 2021, 20, 176.	2.7	10
1093	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2021, 51, 409.	0.7	10
1094	Stroke prevention in atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 501-510.	2.3	10
1095	Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.	1.7	10
1096	Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices: Dynamic Changes in Episodes and Predictors of Incident Atrial Fibrillation. <i>Biology</i> , 2022, 11, 443.	1.3	10
1097	Managing Uncertainty: Physicians' Decision Making for Stroke Prevention for Patients with Atrial Fibrillation and Intracerebral Hemorrhage. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1603-1611.	1.8	10
1098	Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024319.	1.6	10

#	ARTICLE	IF	CITATIONS
1099	Photoplethysmography-Based Machine Learning Approaches for Atrial Fibrillation Prediction. <i>JACC Asia</i> , 2021, 1, 399-408.	0.5	10
1100	Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e37970.	2.1	10
1101	Oral anticoagulants and outcomes in adults ≥80 years with atrial fibrillation: A global federated health network analysis. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2386-2392.	1.3	10
1102	Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. <i>JAMA Network Open</i> , 2022, 5, e2213945.	2.8	10
1103	Factor X inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 799-804.	1.9	9
1104	Inflammation, arrhythmia burden and the thrombotic consequences of atrial fibrillation. <i>European Heart Journal</i> , 2004, 25, 1761-1761.	1.0	9
1105	Effects of dietary fat intake in sudden death: Reduction of death with omega-3 fatty acids. <i>Current Cardiology Reports</i> , 2004, 6, 371-378.	1.3	9
1106	Antithrombotic therapy for congestive heart failure. <i>International Journal of Clinical Practice</i> , 2005, 60, 36-47.	0.8	9
1107	Hypertension, stroke and the impact of atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1287-1289.	0.6	9
1108	Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint. <i>Europace</i> , 2010, 12, 608-610.	0.7	9
1109	Nebivolol for the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1733-1746.	1.9	9
1110	Lone Atrial Fibrillation: Where Are We Now?. <i>Hospital Practice (1995)</i> , 2011, 39, 17-31.	0.5	9
1111	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S8976.	0.6	9
1112	Tratamiento antitrombótico y tipo de stent en pacientes con fibrilación auricular a los que se practica una intervención coronaria percutánea. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 12-16.	0.6	9
1113	Atrial Fibrillation in Cryptogenic Stroke. <i>Stroke</i> , 2014, 45, 3184-3185.	1.0	9
1114	Nonsteroidal anti-inflammatory drugs and bleeding risk in anticoagulated patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 963-965.	0.6	9
1115	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	0.8	9
1116	Recalibration of the HAS-BLED Score. <i>Chest</i> , 2016, 149, 311-314.	0.4	9

#	ARTICLE	IF	CITATIONS
1117	Risk Stratification Models in Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 505-513.	1.5	9
1118	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. <i>International Journal of Cardiology</i> , 2017, 248, 166-172.	0.8	9
1119	The relationship of renal function to outcome: A post hoc analysis from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) study. <i>American Heart Journal</i> , 2017, 193, 16-22.	1.2	9
1120	A happy and prosperous New Year 2017 with 'Thrombosis and Haemostasis'. and our 60th Anniversary!. <i>Thrombosis and Haemostasis</i> , 2017, 117, 01-02.	1.8	9
1121	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , 2018, 132, 149-159.	3.1	9
1122	Multiple biomarkers and arrhythmia outcome following catheter ablation of atrial fibrillation: The Guangzhou Atrial Fibrillation Project. <i>Journal of Arrhythmia</i> , 2018, 34, 617-625.	0.5	9
1123	Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 2049-2054.	0.7	9
1124	Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE). <i>International Journal of Cardiology</i> , 2019, 274, 126-131.	0.8	9
1125	Association between epicardial adipose tissue and embolic stroke after catheter ablation of atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2209-2216.	0.8	9
1126	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. <i>European Journal of Internal Medicine</i> , 2020, 80, 35-44.	1.0	9
1127	Current and emerging drug treatment strategies for peripheral arterial disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1603-1616.	0.9	9
1128	Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 197-198.	1.4	9
1129	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. <i>Thrombosis Research</i> , 2020, 191, 1-8.	0.8	9
1130	Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 68-73.	1.4	9
1131	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021, 23, 314-322.	0.7	9
1132	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 715.	1.0	9
1133	Prevalence/incidence of atrial fibrillation based on integrated medical/pharmacy claims, and association with comorbidity profiles/multimorbidity in a large US adult cohort. <i>International Journal of Clinical Practice</i> , 2021, 75, e14042.	0.8	9
1134	Predicting Silent Atrial Fibrillation in the Elderly: A Report from the NOMED-AF Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2321.	1.0	9

#	ARTICLE	IF	CITATIONS
1135	The Role of Acceptance and Commitment Therapy in Cardiovascular and Diabetes Healthcare: A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8126.	1.2	9
1136	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.	0.7	9
1137	Association Between Change in Metabolic Syndrome Status and Risk of Incident Atrial Fibrillation: A Nationwide Population-Based Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020901.	1.6	9
1138	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.4	9
1139	Noninvasive Monitoring for Early Detection of Atrial Fibrillation: rationale and design of the NOMED-AF study. <i>Kardiologia Polska</i> , 2018, 76, 1482-1485.	0.3	9
1140	Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 730-738.	1.8	9
1141	Cardiovascular disease prevention: Risk factor modification at the heart of the matter. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 17, 100291.	1.3	9
1142	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	1.0	9
1143	Targeted vs. full population screening costs for incident atrial fibrillation and AF-related stroke for a healthy population aged 65 years in the United Kingdom. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 892-898.	1.8	9
1144	Atrial Fibrillation: Should we Target Platelets or the Coagulation Pathway?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 370-371.	0.9	8
1145	Preventing Stroke in Atrial Fibrillation: The SPORTIF Programme. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 25-30.	0.5	8
1146	Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1235-1243.	0.9	8
1147	Platelet adhesion in atrial fibrillation. <i>Thrombosis Research</i> , 2007, 120, 623-629.	0.8	8
1148	Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 473-481.	0.6	8
1149	Antithrombotic therapy for heart failure in sinus rhythm. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 705-717.	1.0	8
1150	Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding. <i>Europace</i> , 2010, 12, 761-763.	0.7	8
1151	Benefit-Risk Assessment of Dronedarone in the Treatment of Atrial Fibrillation. <i>Drug Safety</i> , 2013, 36, 93-110.	1.4	8
1152	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. <i>PLoS ONE</i> , 2015, 10, e0128492.	1.1	8

#	ARTICLE	IF	CITATIONS
1153	Small-size Microparticles as Indicators of Acute Decompensated State in Ischemic Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 951-958.	0.4	8
1154	Altered fibrin clot structure in patients with atrial fibrillation and worsening renal function. <i>Thrombosis and Haemostasis</i> , 2016, 116, 408-409.	1.8	8
1155	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 257-271.	1.0	8
1156	Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 254, 136-141.	0.8	8
1157	New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 71-86.	1.9	8
1158	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	1.1	8
1159	Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 491-498.	0.8	8
1160	Novel Echocardiographic Biomarkers in the Management of Atrial Fibrillation. <i>Current Cardiovascular Imaging Reports</i> , 2019, 12, 1.	0.4	8
1161	Time trends in use of the CHADS ₂ and CHA ₂ DS ₂ VASc scores, and the geographical and specialty uptake of these scores from a popular online clinical decision tool and medical reference. <i>International Journal of Clinical Practice</i> , 2019, 73, e13280.	0.8	8
1162	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2360-2369.	1.4	8
1163	Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. <i>European Journal of Internal Medicine</i> , 2020, 79, 31-36.	1.0	8
1164	Impact of atrial fibrillation in critically ill patients admitted to a stepdown unit. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13317.	1.7	8
1165	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. <i>Drugs</i> , 2020, 80, 995-1005.	4.9	8
1166	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f81-f83.	1.4	8
1167	The heart in hypertension. <i>Journal of Human Hypertension</i> , 2021, 35, 383-386.	1.0	8
1168	Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: the Fushimi AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 163-171.	1.8	8
1169	Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1057-1069.	1.9	8
1170	Myocardial Strain Imaging in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2021, 23, 24.	1.5	8

#	ARTICLE	IF	CITATIONS
1171	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. <i>Cancer Medicine</i> , 2021, 10, 4405-4414.	1.3	8
1172	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs clinical trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 282-289.	1.1	8
1173	Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment. <i>PLoS Medicine</i> , 2021, 18, e1003730.	3.9	8
1174	Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 651-658.	1.8	8
1175	Oral anticoagulation improves survival in very elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>International Journal of Stroke</i> , 2022, 17, 661-668.	2.9	8
1176	Prevalence of atrial fibrillation and outcomes in older long-term care residents: a systematic review. <i>Age and Ageing</i> , 2021, 50, 744-757.	0.7	8
1177	Revisiting the risks of incident atrial fibrillation: a narrative review. Part 2. <i>Kardiologia Polska</i> , 2019, 77, 515-524.	0.3	8
1178	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. <i>Annals of Neurology</i> , 2022, 91, 78-88.	2.8	8
1179	Prognosis and treatment of atrial fibrillation in Asian cities: 1-year review of the Asia-Pacific Heart Rhythm Society Atrial Fibrillation Registry. <i>Europace</i> , 2022, 24, 1889-1898.	0.7	8
1180	Lipid profile, lipid ratios, apolipoproteins, and risk of cardiometabolic multimorbidity in men: The Kuopio Ischaemic Heart Disease Risk Factor Study. <i>Lipids</i> , 2022, 57, 141-149.	0.7	8
1181	Patterns in atrial fibrillation management and "real-world" adherence to guidelines in the Balkan Region: an overview of the Balkan atrial fibrillation survey. <i>European Heart Journal</i> , 2015, 36, 1943-4.	1.0	8
1182	Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 1057-1068.	1.5	8
1183	Risk of Dementia After Smoking Cessation in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2022, 5, e2217132.	2.8	8
1184	Clustering of Unhealthy Lifestyle and the Risk of Adverse Events in Patients With Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8
1185	Anticoagulation for heart failure in sinus rhythm. , 2000, , CD003336.		7
1186	Hibernating myocardium in heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 111-122.	0.6	7
1187	Platelet microparticles and platelet adhesion: Therapeutic implications for the prevention and treatment of stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 251-258.	0.4	7
1188	Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 753-754.	1.8	7

#	ARTICLE	IF	CITATIONS
1189	Using the CHA2DS2-VASc score for stroke risk stratification in atrial fibrillation: a clinical perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 259-262.	0.6	7
1190	Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2013, 110, 340-348.	1.8	7
1191	Rhythm outcomes after catheter ablation of atrial fibrillation. <i>Hamostaseologie</i> , 2014, 34, 9-19.	0.9	7
1192	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 585-599.	0.9	7
1193	Antidotes to non-vitamin K oral anticoagulants: necessary or not?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1573-1576.	0.9	7
1194	Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. <i>International Journal of Cardiology</i> , 2015, 185, 322-327.	0.8	7
1195	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2015, 201, 195-199.	0.8	7
1196	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. <i>International Journal of Cardiology</i> , 2015, 181, 247-254.	0.8	7
1197	How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring. <i>Circulation</i> , 2016, 133, 1290-1295.	1.6	7
1198	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. <i>Europace</i> , 2016, 18, 1507-1513.	0.7	7
1199	Atrial Fibrillation and Stroke. <i>Cardiology Clinics</i> , 2016, 34, 317-328.	0.9	7
1200	Drug-induced liver injury with oral anticoagulants: a threat or not?. <i>Heart</i> , 2017, 103, 809-811.	1.2	7
1201	Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death. <i>Europace</i> , 2018, 20, 1584-1590.	0.7	7
1202	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 537-541.	1.6	7
1203	Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. <i>American Journal of Cardiology</i> , 2019, 123, 1921-1926.	0.7	7
1204	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020, 22, 250-258.	0.7	7
1205	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48.	0.7	7
1206	The CHA2DS2-VASc score and Geriatric Multidimensional Assessment tools in elderly patients with persistent atrial fibrillation undergoing electrical cardioversion. A link with arrhythmia relapse?. <i>European Journal of Internal Medicine</i> , 2020, 82, 56-61.	1.0	7

#	ARTICLE	IF	CITATIONS
1207	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. <i>Annals of Medicine</i> , 2020, 52, 300-309.	1.5	7
1208	Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-CAF. <i>ESC Heart Failure</i> , 2020, 7, 2679-2689.	1.4	7
1209	Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1390-1400.	1.1	7
1210	Thoracoscopic Left Atrial Appendage Excision Plus Ablation for Atrial Fibrillation to Prevent Stroke. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 61-67.	0.4	7
1211	Endothelial dysfunction and vascular maladaptation in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13477.	1.7	7
1212	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 902-908.	1.2	7
1213	Clinical prediction of genotypes in hypertrophic cardiomyopathy: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13593.	1.7	7
1214	Predictors of ischemic stroke for low-risk patients with atrial fibrillation: A matched case-control study. <i>Heart Rhythm</i> , 2021, 18, 702-708.	0.3	7
1215	Comparison among random forest, logistic regression, and existing clinical risk scores for predicting outcomes in patients with atrial fibrillation: A report from the RHYTHM registry. <i>Clinical Cardiology</i> , 2021, 44, 1305-1315.	0.7	7
1216	Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban. <i>Cancer Medicine</i> , 2021, 10, 7079-7088.	1.3	7
1217	One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>Journal of Arrhythmia</i> , 2021, 37, 1227-1239.	0.5	7
1218	Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study. <i>American Heart Journal</i> , 2021, 242, 123-131.	1.2	7
1219	Risk of Atrial Fibrillation in Young Adults With Isolated Diastolic, Isolated Systolic, and Systolic-Diastolic Hypertension. <i>Hypertension</i> , 2021, 78, 1248-1258.	1.3	7
1220	Atrial fibrillation is more frequently associated with non-obstructive coronary lesions: The Bialystok Coronary Project. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 1029-1036.	0.3	7
1221	Post myocardial infarction and atrial fibrillation: Thromboprophylaxis and risk stratification using the CHA2DS2-VASc score. <i>Cardiology Journal</i> , 2014, 21, 451-453.	0.5	7
1222	Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2893-2904.	1.8	7
1223	Impact of Physical Activity on All-Cause Mortality According to Specific Cardiovascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 811058.	1.1	7
1224	A very happy new year 2014 from Thrombosis and Haemostasis! Reflections on the past, the present and the future. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1-2.	1.8	7

#	ARTICLE	IF	CITATIONS
1225	Non-alcoholic Fatty Liver Disease and the Risk of Incident Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 832023.	1.1	7
1226	Clinical risk factors for retinal artery occlusions: a nationwide caseâ€“control study. <i>International Ophthalmology</i> , 2022, 42, 2483-2491.	0.6	7
1227	Alcohol and cardiovascular disease--more than one paradox to consider. Alcohol and hypertension--does it matter? (no!). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 11-4.	1.5	7
1228	Relationship between Serum 25-Hydroxyvitamin D Level and Risk of Recurrent Stroke. <i>Nutrients</i> , 2022, 14, 1908.	1.7	7
1229	Clinical utility and prognostic implications of the <sc>4Sâ€“AF</sc> scheme: Report from Asia Pacific Heart Rhythm Society Atrial Fibrillation Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	7
1230	Ethnicity and arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 92-95.	0.9	6
1231	Ximelagatran for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 551-563.	0.6	6
1232	Effects of low osmolar contrast (iomeprol) on haemorheology and platelet activation in patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 189-194.	1.0	6
1233	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. <i>Annals of Medicine</i> , 2009, 41, 608-618.	1.5	6
1234	Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. <i>European Journal of Heart Failure</i> , 2010, 12, 254-259.	2.9	6
1235	New oral anticoagulants in heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 966-973.	2.9	6
1236	Predictive value of atrial highâ€“rate episodes for arterial stiffness and endothelial dysfunction in dualâ€“chamber pacemaker patients. <i>European Journal of Clinical Investigation</i> , 2014, 44, 13-21.	1.7	6
1237	Prediction of stroke in patients without atrial fibrillation using the CHADS₂ and CHA₂DS₂-VASc scores: a justification for more widespread thromboprophylaxis?. <i>Heart</i> , 2014, 100, 1485-1486.	1.2	6
1238	Ventricular-arterial coupling in obstructive sleep apnea. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 624-629.	2.3	6
1239	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 45-62.	1.0	6
1240	Development and validation of a new assay for assessing clot integrity. <i>Vascular Pharmacology</i> , 2015, 71, 102-107.	1.0	6
1241	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2015, 46, 2830-2837.	1.0	6
1242	Difficult situations in anticoagulation after stroke. <i>Current Opinion in Neurology</i> , 2016, 29, 42-48.	1.8	6

#	ARTICLE	IF	CITATIONS
1243	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 386-392.	1.6	6
1244	Ischemic stroke risk in East Asian patients with CHA ₂ DS ₂ -VASc score of 1: systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 145-150.	0.6	6
1245	Renin-angiotensin blockade in atrial fibrillation: where are we now?. <i>Journal of Human Hypertension</i> , 2017, 31, 425-426.	1.0	6
1246	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. <i>American Journal of Medicine</i> , 2017, 130, 773-779.	0.6	6
1247	Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. <i>International Journal of Clinical Practice</i> , 2017, 71, e12974.	0.8	6
1248	Atrial fibrillation and hypertrophic cardiomyopathy: co-existing conditions with additive risks. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 340-341.	0.4	6
1249	In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 127-134.	0.9	6
1250	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019, 83, 2434-2442.	0.7	6
1251	Sex-related risks of recurrence of atrial fibrillation after ablation: Insights from the Guangzhou Atrial Fibrillation Ablation Registry. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 171-179.	0.7	6
1252	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019, 48, 236-243.	0.8	6
1253	Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 37-47.	1.0	6
1254	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2020, 109, 802-809.	1.5	6
1255	Temporal trends of catheter ablation for patients with atrial fibrillation: A Korean nationwide population-based study. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2616-2625.	0.8	6
1256	Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2713.	1.0	6
1257	Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2020, 74, e13589.	0.8	6
1258	Device-Pocket Hematoma after Cardiac Implantable Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008372.	2.1	6
1259	Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f84-f92.	1.4	6
1260	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1061-1070.	0.9	6

#	ARTICLE	IF	CITATIONS
1261	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE, 2021, 16, e0249524.	1.1	6
1262	Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity. Advances in Therapy, 2021, 38, 3166-3184.	1.3	6
1263	Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis. Endocrine-Related Cancer, 2021, 28, 325-335.	1.6	6
1264	Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. PLoS ONE, 2016, 11, e0152269.	1.1	6
1265	miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients. Annals of Translational Medicine, 2016, 4, 200-200.	0.7	6
1266	Mobile Health for Cardiovascular Disease: The New Frontier for AF Management: Observations from the Huawei Heart Study and mAFA-II Randomised Trial. Arrhythmia and Electrophysiology Review, 2020, 9, 5-7.	1.3	6
1267	Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Clinical Research in Cardiology, 2022, 111, 1040-1047.	1.5	6
1268	Oral anti-coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study. British Journal of Haematology, 2022, 197, 223-231.	1.2	6
1269	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESCâ€EHRA EURObservational research programme in atrial fibrillation general long-term registry. European Journal of Clinical Investigation, 2022, 52, e13773.	1.7	6
1270	Frequent premature atrial contractions as a signalling marker of atrial cardiomyopathy, incident atrial fibrillation, and stroke. Cardiovascular Research, 2023, 119, 429-439.	1.8	6
1271	Incident and recurrent myocardial infarction (MI) in relation to comorbidities: Prediction of outcomes using machine learning algorithms. European Journal of Clinical Investigation, 2022, , e13777.	1.7	6
1272	Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study. Clinical Cardiology, 2022, 45, 91-100.	0.7	6
1273	Drug Interactions Affecting Antiarrhythmic Drug Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, 101161CIRCEP121007955.	2.1	6
1274	Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases. Journal of Thrombosis and Thrombolysis, 2022, 54, 33-46.	1.0	6
1275	Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials. International Journal of Stroke, 2023, 18, 392-399.	2.9	6
1276	Resistant hypertension and the birmingham hypertension square. Current Hypertension Reports, 2001, 3, 203-208.	1.5	5
1277	Stroke prevention in atrial fibrillation patients. Expert Opinion on Pharmacotherapy, 2010, 11, 2331-2350.	0.9	5
1278	New Anticoagulation Drugs for Atrial Fibrillation. Clinical Pharmacology and Therapeutics, 2011, 90, 502-506.	2.3	5

#	ARTICLE	IF	CITATIONS
1279	What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?. <i>Advances in Therapy</i> , 2011, 28, 1-12.	1.3	5
1280	Role of the CHADS 2 Score in Acute Coronary Syndromes. <i>Chest</i> , 2012, 141, 1375-1376.	0.4	5
1281	Bleeding Risk Assessment in Patients With Atrial Fibrillation Who Are Taking Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2013, 41, 71-78.	0.5	5
1282	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2130-2132.	1.9	5
1283	Optimizing stroke prevention in elderly patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2121-2123.	1.9	5
1284	The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden. <i>Europace</i> , 2017, 19, 1767-1775.	0.7	5
1285	Applicability of the modified CHA 2 DS 2 -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017, 38, e21-e22.	1.0	5
1286	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12929.	1.7	5
1287	Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from <scp>FANTASIA</scp> Registry. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12910.	1.7	5
1288	Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non- vitamin K antagonist oral anticoagulants. <i>American Heart Journal</i> , 2018, 198, 166-168.	1.2	5
1289	Predicting recurrent atrial fibrillation after catheter ablation. <i>Europace</i> , 2018, 20, f460-f461.	0.7	5
1290	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion of) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 29</i>		
1291	Renal Function and Risk Stratification of Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2018, 49, 2904-2909.	1.0	5
1292	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. <i>Europace</i> , 2019, 21, 1759-1761.	0.7	5
1293	Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding. <i>Expert Review of Hematology</i> , 2019, 12, 845-855.	1.0	5
1294	Predicting stroke in patients without atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13103.	1.7	5
1295	Recommendations on stroke prevention for patients having a CHA2DS2-VASc score of 1 (males) or 2 (females) in 2019 atrial fibrillation guidelines. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 427-428.	2.3	5
1296	Anticoagulation in elderly patients with nonvalvular atrial fibrillation: A balancing act. <i>Heart Rhythm</i> , 2019, 16, 38-40.	0.3	5

#	ARTICLE	IF	CITATIONS
1297	Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation. <i>American Heart Journal</i> , 2019, 208, 120-122.	1.2	5
1298	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 587-600.	0.6	5
1299	Anticoagulant Therapy in Initially Low-Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors. <i>Journal of the American Heart Association</i> , 2020, 9, e016271.	1.6	5
1300	Sensitivity and specificity of blood-fluid levels for oral anticoagulant-associated intracerebral haemorrhage. <i>Scientific Reports</i> , 2020, 10, 15529.	1.6	5
1301	What Is the Ideal Blood Pressure Threshold for the Prevention of Atrial Fibrillation in Elderly General Population?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2988.	1.0	5
1302	Stroke prevention in elderly patients with non-valvular atrial fibrillation in the BALKANAF survey. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13200.	1.7	5
1303	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 788-790.	1.9	5
1304	Baseline factors associated with early and late death in intracerebral haemorrhage survivors. <i>European Journal of Neurology</i> , 2020, 27, 1257-1263.	1.7	5
1305	Atrial fibrillation and cardiac arrhythmia associated with acute dental infection: A systematic literature review and case report. <i>International Journal of Clinical Practice</i> , 2021, 75, e13875.	0.8	5
1306	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 31-39.	1.4	5
1307	Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation. <i>Cardiovascular Research</i> , 2021, 117, 1609-1611.	1.8	5
1308	Exercise rehabilitation associates with lower mortality and hospitalisation in cardiovascular disease patients with COVID-19. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e32-e34.	0.8	5
1309	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions. <i>Current Cardiology Reports</i> , 2021, 23, 136.	1.3	5
1310	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. <i>F1000Research</i> , 2016, 5, 2887.	0.8	5
1311	What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2012, 42, 35-44.	0.2	5
1312	Oral Anticoagulation Timing in Patients with Acute Ischemic Stroke and Atrial Fibrillation. <i>Thrombosis and Haemostasis</i> , 2022, 122, 939-950.	1.8	5
1313	Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2021, 41, 941-953.	1.1	5
1314	Are low doses of non-vitamin K antagonists effective in Chinese patients with atrial fibrillation? A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>International Journal of Stroke</i> , 2022, 17, 848-854.	2.9	5

#	ARTICLE	IF	CITATIONS
1315	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	1.5	5
1316	Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2021, 10, e022628.	1.6	5
1317	Integrated Care of Atrial Fibrillation Using the ABC (Atrial fibrillation Better Care) Pathway Improves Clinical Outcomes in Chinese Population: An Analysis From the Chinese Atrial Fibrillation Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 762245.	1.1	5
1318	Palpitations in the Cancer Patient. <i>European Cardiology Review</i> , 2021, 16, e45.	0.7	5
1319	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 891.	1.0	5
1320	A happy new year from Thrombosis and Haemostasis. A 5 year reflection from the editorial team. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1-2.	1.8	5
1321	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
1322	Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>PLoS ONE</i> , 2022, 17, e0264538.	1.1	5
1323	Artificial intelligence to detect abnormal heart rhythm from scanned electrocardiogram tracings. <i>Journal of Arrhythmia</i> , 2022, 38, 425-431.	0.5	5
1324	Safety and efficacy of direct oral anticoagulants in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 840-851.	1.8	5
1325	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study. <i>Stroke</i> , 2022, 53, 2559-2568.	1.0	5
1326	Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2022, 7, 583.	3.0	5
1327	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. <i>EuroIntervention</i> , 2022, 18, e292-e302.	1.4	5
1328	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Internal Medicine</i> , 2022, 103, 41-49.	1.0	5
1329	Long-Term Cardiac Monitoring After Embolic Stroke of Undetermined Source: Search Longer, Look Harder. <i>American Journal of Medicine</i> , 2022, 135, e311-e317.	0.6	5
1330	Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 939-951.	0.9	5
1331	Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3788.	1.0	5
1332	Sinus rhythm restoration and improved outcomes in patients with acute ischemic stroke and in-hospital paroxysmal atrial fibrillation. <i>European Stroke Journal</i> , 2022, 7, 421-430.	2.7	5

#	ARTICLE	IF	CITATIONS
1333	Apolipoprotein E and Cerebral Small Vessel Disease Markers in Patients With Intracerebral Haemorrhage. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000200851.	1.5	5
1334	Antithrombotic Therapy: Standard Therapy in Essential Hypertension?. <i>Progress in Cardiovascular Diseases</i> , 2006, 49, 11-15.	1.6	4
1335	Peripheral artery disease and hypertension: the relation between ankle-brachial index and mortality. <i>Journal of Human Hypertension</i> , 2007, 21, 762-765.	1.0	4
1336	Vital exhaustion and cardiovascular disease: Are circulating fibrinogen and D-dimer levels a plausible link?. <i>Stress</i> , 2008, 11, 247-249.	0.8	4
1337	Insights from the RCPE UK Consensus Conference on approaching the comprehensive management of atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 697-700.	0.6	4
1338	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 946-947.	1.2	4
1339	New advances in the treatment of atrial fibrillation: focus on stroke prevention. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2193-2204.	0.9	4
1340	Use of Novel Oral Anticoagulants in Patients With Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 285.	0.4	4
1341	Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1362-1373.	1.1	4
1342	Stroke prevention in atrial fibrillation: changing concepts. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 76-79.	1.4	4
1343	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 937-948.	1.5	4
1344	Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2661-2678.	0.9	4
1345	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 210.	1.3	4
1346	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. <i>PLoS ONE</i> , 2016, 11, e0163171.	1.1	4
1347	Premature Cardiac Aging in South Asian Compared to Afro-Caribbean Subjects in a Community-Based Screening Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	4
1348	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2033-2047.	0.9	4
1349	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Research in Cardiology</i> , 2017, 106, 420-427.	1.5	4
1350	Atrial Fibrillation and End Stage Renal Failure in Patients Receiving Dialysis: Balancing the Risks and Benefits of Stroke Prevention. <i>Canadian Journal of Cardiology</i> , 2017, 33, 705-707.	0.8	4

#	ARTICLE	IF	CITATIONS
1351	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , 2017, 10, 1005-1022.	1.0	4
1352	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Interventional Cardiology Clinics</i> , 2017, 6, 91-117.	0.2	4
1353	Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity-Weighted Cohort Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	4
1354	Role of chronic kidney disease and atrial fibrillation in outcomes of patients with ischemic stroke. <i>European Journal of Neurology</i> , 2018, 25, 1009-1010.	1.7	4
1355	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018, 72, e13069.	0.8	4
1356	Predictors of diastolic dysfunction in ethnic groups: observations from the Hypertensive Cohort of The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). <i>Journal of Human Hypertension</i> , 2018, 32, 477-486.	1.0	4
1357	Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 847-855.	0.4	4
1358	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.	0.7	4
1359	Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?. <i>European Heart Journal</i> , 2019, 40, 3779-3781.	1.0	4
1360	Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. <i>Thrombosis Research</i> , 2019, 177, 180-186.	0.8	4
1361	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988518.	0.7	4
1362	Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study. <i>Scientific Reports</i> , 2019, 9, 18055.	1.6	4
1363	Breaking the rules for studies using real-world observational data: the case of direct-acting anticoagulants and antiepileptic drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 155-156.	1.4	4
1364	Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices. <i>Europace</i> , 2020, 22, 173-176.	0.7	4
1365	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020, 22, 11-112.	0.0	4
1366	A greater burden of atrial fibrillation is associated with worse endothelial dysfunction in hypertension. <i>Journal of Human Hypertension</i> , 2021, 35, 667-677.	1.0	4
1367	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1107-1114.	1.8	4
1368	Haptoglobin genotype and outcome after spontaneous intracerebral haemorrhage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 298-304.	0.9	4

#	ARTICLE	IF	CITATIONS
1369	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1374-1380.	1.5	4
1370	A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!. <i>Thrombosis and Haemostasis</i> , 2020, 120, 001-004.	1.8	4
1371	Clinical factors related to successful or unsuccessful cardioversion in the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) randomized trial. <i>Journal of Arrhythmia</i> , 2020, 36, 430-438.	0.5	4
1372	Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1090-1093.	1.0	4
1373	Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated. <i>Journal of Human Hypertension</i> , 2021, 35, 301-303.	1.0	4
1374	Thrombosis and Haemostasis 2020 Editors' Choice Papers. <i>Thrombosis and Haemostasis</i> , 2021, 121, 109-114.	1.8	4
1375	Looking Back on 2020, Looking Forward to 2021. <i>Thrombosis and Haemostasis</i> , 2021, 121, 001-003.	1.8	4
1376	Fat, Sugar or Gut Microbiota in Reducing Cardiometabolic Risk: Does Diet Type Really Matter?. <i>Nutrients</i> , 2021, 13, 639.	1.7	4
1377	Nonatrial Fibrillation Patients With Complete P Wave Disappearance. <i>Stroke</i> , 2021, 52, 1074-1078.	1.0	4
1378	Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1505.	1.0	4
1379	Clinical outcomes following rhythm control for atrial fibrillation: is early better?. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 277-287.	0.6	4
1380	Hypertension and atrial fibrillation: Closing a virtuous circle. <i>PLoS Medicine</i> , 2021, 18, e1003598.	3.9	4
1381	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. <i>Journal of Clinical Medicine</i> , 2021, 10, 3357.	1.0	4
1382	Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1563-1565.	2.9	4
1383	“Rise of the machines”: the next frontier in individualized medicine. <i>Cardiovascular Research</i> , 2021, 117, e129-e131.	1.8	4
1384	Targeted atrial fibrillation detection in COVID-19 vaccination clinics. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 526-528.	1.8	4
1385	Impact of abdominal obesity on outcomes of catheter ablation in Korean patients with atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2021, 75, e14696.	0.8	4
1386	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	1.6	4

#	ARTICLE	IF	CITATIONS
1387	Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk?. <i>European Heart Journal</i> , 2021, 42, 4049-4052.	1.0	4
1388	Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 435.	1.0	4
1389	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAME-TT ₂ /R ₂ score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. <i>BMJ Open</i> , 2021, 11, e051987.	0.8	4
1390	Newly diagnosed atrial fibrillation and hospital utilization in heart failure: a nationwide cohort study. <i>ESC Heart Failure</i> , 2021, 8, 4808-4819.	1.4	4
1391	Atrial high rate episodes as a marker of atrial cardiomyopathy: In the quest of the Holy Grail. Author's reply. <i>European Journal of Internal Medicine</i> , 2022, 98, 115-116.	1.0	4
1392	Effects of multimorbidity on incident COVID-19 events and its interplay with COVID-19 event status on subsequent incident myocardial infarction (MI). <i>European Journal of Clinical Investigation</i> , 2022, , e13760.	1.7	4
1393	Altered cardiac and vascular stiffness in pregnancy after a hypertensive pregnancy. <i>Journal of Human Hypertension</i> , 2023, 37, 189-196.	1.0	4
1394	Relation of the "Atrial Fibrillation Better Care (ABC) Pathway"™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.	1.1	4
1395	Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3847-3855.	1.1	4
1396	Exercise-Based Cardiac Rehabilitation Associates with Lower Major Adverse Cardiovascular Events in People with Stroke. <i>Cerebrovascular Diseases</i> , 2022, 51, 488-492.	0.8	4
1397	Cardiovascular considerations in management of patients with Turner syndrome. <i>Trends in Cardiovascular Medicine</i> , 2021, , .	2.3	4
1398	Atrial Fibrillation Specific Exercise Rehabilitation: Are We There Yet?. <i>Journal of Personalized Medicine</i> , 2022, 12, 610.	1.1	4
1399	Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIA Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856222.	1.1	4
1400	Measurement of Diastolic Blood Pressure in Obstetrical Research. <i>Hypertension in Pregnancy</i> , 1996, 15, 135-137.	0.5	3
1401	Hormone Replacement Therapy and Cardiovascular Risk. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002, 1, 95-103.	1.8	3
1402	Rheumatoid disease and the heart: from epidemiology to echocardiography. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 65-76.	1.9	3
1403	Stroke: ethnic differences do exist. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1769-1771.	1.4	3
1404	Atrial fibrillation and stroke prevention. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1523-1530.	1.4	3

#	ARTICLE	IF	CITATIONS
1405	Stroke prevention in atrial fibrillation: antiplatelet therapy revisited. <i>European Heart Journal</i> , 2007, 28, 926-928.	1.0	3
1406	Stroke prevention in atrial fibrillation – things can only get better. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 575-577.	1.1	3
1407	Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones. <i>International Journal of Clinical Practice</i> , 2010, 64, 138-140.	0.8	3
1408	Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1191-1196.	1.9	3
1409	New Anticoagulants for the Prevention of Deep Venous Thrombosis. <i>Pharmacoeconomics</i> , 2009, 27, 793-795.	1.7	3
1410	Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1398-1399.	1.2	3
1411	Vascular ventricular coupling in patients with malignant phase hypertension: the West Birmingham malignant hypertension project. <i>Hypertension Research</i> , 2012, 35, 725-728.	1.5	3
1412	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2414-2415.	1.9	3
1413	Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?. <i>Current Hypertension Reports</i> , 2012, 14, 183-192.	1.5	3
1414	Safety and Efficacy of New Anticoagulants in Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 18-25.	1.3	3
1415	Warfarin for stroke prevention in atrial fibrillation: time to switch?. <i>International Journal of Clinical Practice</i> , 2013, 67, 603-605.	0.8	3
1416	Oral anticoagulation for heart failure in sinus rhythm: from evidence to clinical recommendations, or not?. <i>European Journal of Heart Failure</i> , 2013, 15, 3-4.	2.9	3
1417	The atrial fibrillation epidemic: a validated diagnosis, or not?. <i>Europace</i> , 2014, 16, 1701-1702.	0.7	3
1418	Response. <i>Chest</i> , 2014, 145, 188-189.	0.4	3
1419	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , 2015, 65, 117-117.	0.7	3
1420	Switching from a vitamin K antagonist to a NOAC. <i>Lancet Haematology</i> , 2015, 2, e132-e133.	2.2	3
1421	Intracerebral haemorrhage, atrial fibrillation, and anticoagulation. <i>Lancet</i> , 2015, 386, 1736-1737.	6.3	3
1422	Evaluation of a color coding™ system for the assessment of patients undergoing primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016, 212, 371-376.	0.8	3

#	ARTICLE	IF	CITATIONS
1423	Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin. <i>Annals of Medicine</i> , 2016, 48, 275-281.	1.5	3
1424	Stroke prevention in atrial fibrillation: can we do better?. <i>Nature Reviews Cardiology</i> , 2016, 13, 511-512.	6.1	3
1425	Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 47-54.	1.3	3
1426	Atrial fibrillation and its complications: a focus on identifying risk factors and risk stratification. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 88-89.	1.4	3
1427	Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 233-244.	1.0	3
1428	To occlude or not? Left atrial appendage occlusion for stroke prevention in atrial fibrillation. <i>Heart</i> , 2017, 103, 93-95.	1.2	3
1429	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1212.	1.2	3
1430	Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2017, 33, 1175-1177.	0.9	3
1431	Stroke Prophylaxis After a New Emergency Department Diagnosis of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 471-472.	1.2	3
1432	Screening for atrial fibrillation: look harder, look longer, and improve stroke outcomes with oral anticoagulation. <i>Europace</i> , 2018, 20, f278-f279.	0.7	3
1433	Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 127-135.	1.8	3
1434	Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation—A Nationwide Cohort Study. <i>Circulation Journal</i> , 2019, 83, 2547-2554.	0.7	3
1435	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , 2019, 21, 690-693.	2.9	3
1436	Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades. <i>Thrombosis and Haemostasis</i> , 2019, 119, 685-687.	1.8	3
1437	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
1438	Thrombosis and Haemostasis 2018 Editor's Choice Papers. <i>Thrombosis and Haemostasis</i> , 2019, 119, 183-186.	1.8	3
1439	Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. <i>European Journal of Heart Failure</i> , 2020, 22, 136-138.	2.9	3
1440	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1867-1881.	0.9	3

#	ARTICLE	IF	CITATIONS
1441	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008477.	2.1	3
1442	Atrial fibrillation: Can it be as easy as CC to ABC?. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13413.	1.7	3
1443	Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 357-365.	1.0	3
1444	Thrombosis and Haemostasis 2019 Editor's Choice Papers. <i>Thrombosis and Haemostasis</i> , 2020, 120, 184-190.	1.8	3
1445	Optimization of atrial fibrillation care: management strategies and quality measures. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 121-133.	1.8	3
1446	Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIA registry. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13431.	1.7	3
1447	Pathophysiological insights into atrial fibrillation: revisiting the electrophysiological substrate, anatomical substrate, and possible insights from proteomics. <i>Cardiovascular Research</i> , 2021, 117, e41-e45.	1.8	3
1448	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORPâ€AF General Longâ€Term Registry. <i>International Journal of Clinical Practice</i> , 2021, 75, e13701.	0.8	3
1449	Embolic Stroke of Undetermined Source: The Need for an Integrated and Holistic Approach to Care. <i>Thrombosis and Haemostasis</i> , 2021, 121, 251-254.	1.8	3
1450	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKANâ€AF survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14080.	0.8	3
1451	Relationship Between Body Mass Index and Incidence of Atrial Fibrillation in Young Japanese Menâ€â€• The Nishimura Health Survey â€•. <i>Circulation Journal</i> , 2021, 85, 243-251.	0.7	3
1452	Acute Dental Periapical Abscess and New-Onset Atrial Fibrillation: A Nationwide, Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2927.	1.0	3
1453	Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. <i>International Journal of Stroke</i> , 2022, 17, 536-544.	2.9	3
1454	Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 435-446.	0.9	3
1455	Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 353-362.	1.4	3
1456	Association of proteinuria and hypertension with incident atrial fibrillation in an elderly population: nationwide data from a community-based elderly cohort. <i>Journal of Hypertension</i> , 2022, 40, 128-135.	0.3	3
1457	Association of proteinuria and incident atrial fibrillation in patients with diabetes mellitus: a population-based senior cohort study. <i>Scientific Reports</i> , 2021, 11, 17013.	1.6	3
1458	Updating a simple clinical score predicting incident atrial fibrillation: The CHEST score or more (mCHEST)?. <i>European Journal of Internal Medicine</i> , 2021, 90, 27-29.	1.0	3

#	ARTICLE	IF	CITATIONS
1459	Beyond atrial fibrillation detection: how digital tools impact the care of patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021, 93, 117-118.	1.0	3
1460	Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention. <i>BMJ: British Medical Journal</i> , 2008, 337, a840-a840.	2.4	3
1461	Monocyte-platelet cross-talk in peripheral artery disease—how much does the pathogenesis of atherosclerosis depend on anatomical location?. <i>Annals of Translational Medicine</i> , 2019, 7, S19-S19.	0.7	3
1462	Recent Progress in Antithrombotic Therapy for Atrial Fibrillation. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 257-273.	0.9	3
1463	Erectile dysfunction in atrial fibrillation: A risk factor for stroke or a reflection of stroke risk factors?. <i>Cardiology Journal</i> , 2015, 22, 359-361.	0.5	3
1464	Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. <i>European Heart Journal</i> , 2021, 42, .	1.0	3
1465	The Impact of Atrial Fibrillation on Outcomes of Peripheral Arterial Disease: Analysis of Routinely Collected Primary Care Data. <i>American Journal of Medicine</i> , 2022, 135, 488-492.	0.6	3
1466	Left Atrial Appendage Morphology Impacts Thrombus Formation Risks in Multi-Physics Atrial Models. , 2021, , .		3
1467	Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>Europace</i> , 2022, 24, 1076-1083.	0.7	3
1468	The Patient Pathway Review for Atrial Fibrillation. <i>Critical Pathways in Cardiology</i> , 2022, 21, 96-102.	0.2	3
1469	Impact of Multimorbidity and Polypharmacy on Clinical Outcomes of Elderly Chinese Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1370.	1.0	3
1470	A comparison of medical therapy and ablation for atrial fibrillation in patients with heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 169-183.	0.6	3
1471	Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol. <i>Journal of Personalized Medicine</i> , 2022, 12, 578.	1.1	3
1472	Lipid levels, apolipoproteins, and risk of incident atrial fibrillation in men: A report from the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD). <i>Journal of Clinical Lipidology</i> , 2022, 16, 447-454.	0.6	3
1473	Atrial Fibrillation Better Care Pathway Adherent Care Improves Outcomes in Chinese Patients With Atrial Fibrillation. <i>JACC Asia</i> , 2022, 2, 422-429.	0.5	3
1474	Atrial fibrillation, a contemporary sign of multimorbidity and irregular social inequity. <i>Lancet Regional Health - Europe</i> , The, 2022, 17, 100395.	3.0	3
1475	Type and Severity of Migraine Determines Risk of Atrial Fibrillation in Women. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	3
1476	Circulating Vitamin D Concentrations and Risk of Atrial Fibrillation: A Mendelian Randomization Study Using Non-deficient Range Summary Statistics. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3

#	ARTICLE	IF	CITATIONS
1477	Effectiveness and Safety of Antithrombotic Medication in Patients With Atrial Fibrillation and Intracranial Hemorrhage: Systematic Review and Meta-Analysis. <i>Stroke</i> , 2022, 53, 3035-3046.	1.0	3
1478	Correspondence. <i>American Journal of Hypertension</i> , 1998, 11, 1266-1267.	1.0	2
1479	Letters. <i>Diabetic Medicine</i> , 1999, 16, 86-87.	1.2	2
1480	Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. <i>Journal of the American College of Cardiology</i> , 2001, 38, 2133-2134.	1.2	2
1481	Psychosocial functioning of adults with congenital heart disease: a neglected area. <i>European Heart Journal</i> , 2003, 24, 2159.	1.0	2
1482	Left ventricular systolic dysfunction and atrial fibrillation in older people in the community: the need for identification, as well as appropriate management. <i>Age and Ageing</i> , 2004, 33, 434-436.	0.7	2
1483	Management of Atrial Fibrillation. <i>Herz</i> , 2006, 31, 849-856.	0.4	2
1484	Cardiac biomarkers: myths, facts and future horizons. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 693-697.	1.5	2
1485	How safe is the antiarrhythmic drug therapy in atrial fibrillation?. <i>Europace</i> , 2009, 11, 837-839.	0.7	2
1486	Renin-angiotensin-aldosterone system blockade in atrial fibrillation and left atrial remodelling. <i>International Journal of Clinical Practice</i> , 2009, 63, 982-985.	0.8	2
1487	Soluble Fms-Like Tyrosine Kinase-1. <i>Circulation Journal</i> , 2010, 74, 2064-2065.	0.7	2
1488	Peripheral artery disease: appreciating the asymptomatic - yet lethal - epidemic. <i>International Journal of Clinical Practice</i> , 2010, 64, 832-835.	0.8	2
1489	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1703-1710.	0.6	2
1490	Dronedaronone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2775-2778.	0.9	2
1491	New concepts and approaches to stroke prevention in the new European Society of Cardiology guidelines for the management of atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1643-1647.	0.6	2
1492	The Improved but Unfinished Business of Stroke Risk Stratification in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 639-641.	0.4	2
1493	Intracerebral Hemorrhage and Warfarin. <i>Stroke</i> , 2011, 42, 2383-2384.	1.0	2
1494	Antithrombotic Management and Type of Stent in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 12-16.	0.4	2

#	ARTICLE	IF	CITATIONS
1495	Stroke Prevention in Atrial Fibrillation in Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 427-435.	1.0	2
1496	Editorial (Thematic Issue: "Lone" Atrial Fibrillation: No Longer Lone or Even Alone). <i>Current Pharmaceutical Design</i> , 2014, 21, 531-532.	0.9	2
1497	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation and Venous Thromboembolism: Where are we Now?. <i>Hospital Practice (1995)</i> , 2014, 42, 153-162.	0.5	2
1498	Vernakalant hydrochloride to treat atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 865-872.	0.9	2
1499	MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation*. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 265-266.	2.3	2
1500	Atrial Fibrillation During Sepsis. <i>Chest</i> , 2014, 146, 1138-1140.	0.4	2
1501	Treatment of Atrial Fibrillation in Patients With Chronic Kidney Disease. <i>Chest</i> , 2016, 149, 891-892.	0.4	2
1502	How to REVISIT the increasing "cereal world" evidence for stroke prevention in non-valvular atrial fibrillation?. <i>Current Medical Research and Opinion</i> , 2016, 32, 2055-2057.	0.9	2
1503	From clinical trials to real-world clinical practice: observations on the direct oral anticoagulants. <i>Lancet Haematology</i> , 2016, 3, e2-e3.	2.2	2
1504	Oral anticoagulation for elderly patients with non-valvular atrial fibrillation: recent insights from randomised trials and the "real world". <i>Heart</i> , 2017, 103, 977-978.	1.2	2
1505	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Cardiology</i> , 2017, 40, 1264-1270.	0.7	2
1506	Hypertension and cardiac arrhythmias. <i>European Heart Journal</i> , 2017, 38, 223-225.	1.0	2
1507	The Importance and Future of Population Screening for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1407-1411.	0.8	2
1508	A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1119-1125.	1.0	2
1509	Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985362.	0.7	2
1510	Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2301-2303.	1.6	2
1511	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 243-244.	0.7	2
1512	Short-Term Outcomes in Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: How Important Is Ethnicity?. <i>Journal of the American Heart Association</i> , 2019, 8, e011953.	1.6	2

#	ARTICLE	IF	CITATIONS
1513	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. <i>Systematic Reviews</i> , 2019, 8, 331.	2.5	2
1514	Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1018-1024.	1.5	2
1515	The year in cardiology: arrhythmias and pacing. <i>European Heart Journal</i> , 2020, 41, 619-625c.	1.0	2
1516	Why Is Atrial Fibrillation So Frequent in Hypertensive Patients?. <i>American Journal of Hypertension</i> , 2020, 33, 1067-1070.	1.0	2
1517	Treatment implications of renal disease in patients with atrial fibrillation: The BALKANAF survey. <i>Journal of Arrhythmia</i> , 2020, 36, 863-873.	0.5	2
1518	Blood pressure targets in atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 2860-2862.	1.0	2
1519	Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease. <i>Circulation</i> , 2020, 141, 1855-1858.	1.6	2
1520	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSUREAF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13221.	1.7	2
1521	The potential for photoplethysmographic (PPG)-based smart devices in atrial fibrillation detection. <i>Expert Review of Medical Devices</i> , 2020, 17, 253-255.	1.4	2
1522	Regional registries on the management of atrial fibrillation: Essential pieces in the global puzzle. <i>IJC Heart and Vasculature</i> , 2020, 26, 100473.	0.6	2
1523	Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: An ancillary analysis from the BOREALIS trial. <i>Journal of Arrhythmia</i> , 2020, 36, 282-288.	0.5	2
1524	Alterations in atrial electrogram amplitude as steady sinus rhythm transitions to paroxysmal atrial fibrillation during continuous monitoring in patients with implantable cardiac devices: Insights from the IMPACT study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1357-1363.	0.8	2
1525	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after <sc>PCI</sc> in patients with atrial fibrillation (a <sc>RE–DUAL) Tj ETQq1 1 0.784314 rrgBT /Ov <i>Cardiology</i> , 2021, 44, 1002-1010.	0.7	2
1526	Aortovascular medicine: what is it?. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 014107682110134.	1.1	2
1527	How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1807-1810.	0.9	2
1528	Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. <i>Clinical Research in Cardiology</i> , 2021, , 1.	1.5	2
1529	Photoplethysmography rhythm interpretation: an essential skill in an era of novel technologies. <i>European Heart Journal Digital Health</i> , 2021, 2, 361-362.	0.7	2
1530	The Prognosis of Baseline Mitral Regurgitation in Patients with Transcatheter Aortic Valve Implantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3974.	1.0	2

#	ARTICLE	IF	CITATIONS
1531	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGram2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4472.	1.0	2
1532	Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. <i>PLoS ONE</i> , 2020, 15, e0240161.	1.1	2
1533	The Potential Role of Edoxaban in Stroke Prevention Guidelines. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 40-43.	1.3	2
1534	Anticoagulation in Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2012, 1, 12.	1.3	2
1535	Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 90.	1.3	2
1536	Preventative Measures of Stroke in Patients With Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012, 4, 399.	0.5	2
1537	Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Riskâ€”The Fushimi AF Registry â€”. <i>Circulation Reports</i> , 2021, 3, 629-638.	0.4	2
1538	Towards Assigning Diagnosis Codes Using Medication History. <i>Lecture Notes in Computer Science</i> , 2020, , 203-213.	1.0	2
1539	Heart rate variability changes following catheter ablation for atrial fibrillation. <i>Kardiologia Polska</i> , 2020, 78, 179-180.	0.3	2
1540	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-42.	0.9	2
1541	Catheter ablation for atrial fibrillation in heart failure: untying the Gordian knot. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 297-306.	0.2	2
1542	Comparison of the HASâ€”BLED versus ORBIT Scores in Predicting Major Bleeding Among Asians Receiving the Directâ€”Acting Oral Anticoagulants. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	2
1543	Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 313.	1.0	2
1544	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. <i>Archives of Medical Science</i> , 2022, , .	0.4	2
1545	Thrombosis and Haemostasis 2021 Editors' Choice Papers. <i>Thrombosis and Haemostasis</i> , 2022, 122, 163-170.	1.8	2
1546	Breast cancer and incident cardiovascular events: A systematic analysis at the nationwide level. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13754.	1.7	2
1547	Telemedical Monitoring Based on Implantable Devicesâ€”the Evolution Beyond the CardioMEMSâ„¢ Technology. <i>Current Heart Failure Reports</i> , 2022, 19, 7-14.	1.3	2
1548	Using the C2HEST Score for Predicting Postoperative Atrial Fibrillation After Cardiac Surgery: A Report From the Western Denmark Heart Registry, the Danish National Patient Registry, and the Danish National Prescription Registry. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3730-3737.	0.6	2

#	ARTICLE	IF	CITATIONS
1549	The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2022, 11, 63.	2.5	2
1550	Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the "transition era"™ to non-vitamin K antagonist oral anticoagulants. <i>Europace</i> , 2022, 24, 871-873.	0.7	2
1551	Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 775564.	1.1	2
1552	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. <i>Journal of General Internal Medicine</i> , 2023, 38, 315-323.	1.3	2
1553	Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (<sc>ChiOTEAF</sc>) registry. <i>Journal of Arrhythmia</i> , 2022, 38, 580-588.	0.5	2
1554	Development and Validation of 3-Year Atrial Fibrillation Prediction Models Using Electronic Health Record With or Without Standardized Electrocardiogram Diagnosis and a Performance Comparison Among Models. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
1555	Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1897-1900.	2.2	2
1556	Social determinants of health and catheter ablation after an incident diagnosis of atrial fibrillation: a Danish nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 0, , .	1.8	2
1557	Diurnal rhythms and hemostatic factors in atrial fibrillation: reply. <i>Journal of the American College of Cardiology</i> , 2001, 37, 970-971.	1.2	1
1558	Calcium antagonists in diabetic hypertension. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 311-318.	2.2	1
1559	Ongoing trials involving angiotensin-converting enzyme inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1633-1643.	1.9	1
1560	Letter to the Editor Biomarkers in Atrial Fibrillation: Further Observations on Biologic Plausibility, Cause and Effect. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 20, 189-190.	1.0	1
1561	Hormone replacement use and cardiovascular function and structure in postmenopausal women. <i>Blood Pressure</i> , 2005, 14, 3-5.	0.7	1
1562	New evidence of anti-inflammatory interventions in atrial fibrillation: reply. <i>European Heart Journal</i> , 2005, 27, 501-501.	1.0	1
1563	Endothelial progenitor cells: from pathophysiology to clinical practice. <i>International Journal of Clinical Practice</i> , 2008, 62, 4-6.	0.8	1
1564	Antithrombotic Therapy Use After Percutaneous Coronary Intervention and Stent Implantation in Patients Taking Chronic Oral Anticoagulation. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 329.	1.1	1
1565	The Endothelium, Arterial Stiffness, and von Willebrand Factor Levels in Hypertensive Women: Effects of Ethnicity. <i>American Journal of Hypertension</i> , 2008, 21, 1275-1276.	1.0	1
1566	Balancing Thromboembolism and Bleeding Risks. <i>Chest</i> , 2009, 136, 1451-1452.	0.4	1

#	ARTICLE	IF	CITATIONS
1567	AZD6140 and bleeding: towards safer antiplatelet therapy?. International Journal of Clinical Practice, 2009, 63, 537-539.	0.8	1
1568	Bleeding risk with oral anticoagulation - new frontiers and new questions. International Journal of Clinical Practice, 2011, 65, 719-721.	0.8	1
1569	Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. Expert Opinion on Pharmacotherapy, 2012, 13, 1087-1090.	0.9	1
1570	Silent cerebral embolism after catheter ablation of atrial fibrillation. International Journal of Clinical Practice, 2012, 66, 118-120.	0.8	1
1571	Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly. International Journal of Clinical Practice, 2012, 66, 2-4.	0.8	1
1572	Finding atrial fibrillation: just keep looking, just keep looking (but remember stroke prevention). Journal of Internal Medicine, 2013, 274, 457-460.	2.7	1
1573	Assess bleeding risk with HAS-BLED and assess stroke risk with CHA2DS2-VASc in patients with atrial fibrillation. Hypertension Research, 2014, 37, 699-700.	1.5	1
1574	Response. Chest, 2014, 145, 419-420.	0.4	1
1575	Common Questions in Anticoagulation Management in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2014, 6, 79-86.	0.7	1
1576	Comparing the "New" R2CHADS2 With the "Old" CHA2DS2-VASc Scores for Predicting Thromboembolism in Patients Undergoing Atrial Fibrillation Ablation: New Does Not Mean Better. Canadian Journal of Cardiology, 2014, 30, 385-387.	0.8	1
1577	Stroke prevention in atrial fibrillation: Where are we now?. Indian Heart Journal, 2015, 67, S1-S3.	0.2	1
1578	Non-steroidal anti-inflammatory drugs and incident atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 115-116.	1.4	1
1579	Recent scientific documents from the European Heart Rhythm Association (EHRA). Europace, 2015, 17, 1161-1163.	0.7	1
1580	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. Current Treatment Options in Neurology, 2015, 17, 331.	0.7	1
1581	Fondaparinux in atrial fibrillation "old dog, new tricks?. Archives of Cardiovascular Diseases, 2015, 108, 85-87.	0.7	1
1582	Not all thromboembolism comes from the left atrial appendage in atrial fibrillation. Heart, 2015, 101, 830-831.	1.2	1
1583	144...Does Home-Based, Slow Deep Breathing Training Reduce Central Sympathetic Outflow and Enhance Baroreflex Sensivity in Primary Hypertension?. Heart, 2015, 101, A83.1-A83.	1.2	1
1584	Ethnic differences in the diurnal variation of symptom onset time for acute ST elevation myocardial infarction " An observational cohort study. International Journal of Cardiology, 2015, 187, 414-416.	0.8	1

#	ARTICLE	IF	CITATIONS
1585	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1155-1163.	0.6	1
1586	Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 949.	3.8	1
1587	Editors'™ Choice 2015 papers in Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 230-232.	1.8	1
1588	Use of non-vitamin K antagonist oral anticoagulants in patients with heart failure and atrial fibrillation: does concomitant kidney disease change our practice?. <i>European Journal of Heart Failure</i> , 2016, 18, 1172-1174.	2.9	1
1589	Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2017, 236, 244-248.	0.8	1
1590	Is atrial fibrillation another manifestation of organ damage in diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 761-762.	5.5	1
1591	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants. <i>Expert Review of Hematology</i> , 2017, 10, 833-845.	1.0	1
1592	Peripheral arterial disease amongst British ethnic minorities in a community based population: The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). <i>International Journal of Clinical Practice</i> , 2017, 71, e12977.	0.8	1
1593	Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study. <i>Journal of Human Hypertension</i> , 2017, 31, 206-211.	1.0	1
1594	Editors' Choice in the 60th Anniversary Year of Thrombosis and Haemostasis: Past, Present and Future. <i>Thrombosis and Haemostasis</i> , 2018, 118, 225-227.	1.8	1
1595	Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease: a nationwide cohort study. <i>European Heart Journal</i> , 2018, 39, .	1.0	1
1596	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. <i>Diabetic Medicine</i> , 2018, 35, 1134-1135.	1.2	1
1597	Reply to "Comment on "Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized clinical trials" by Tse et al". <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2165-2166.	1.1	1
1598	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 150-152.	2.3	1
1599	Atrial Fibrillation and End-Stage COPD. <i>Chest</i> , 2019, 155, 888-889.	0.4	1
1600	Galectin-3 and Î2-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. <i>Scientific Reports</i> , 2019, 9, 6235.	1.6	1
1601	Physician Estimation of Thrombotic and Bleeding Risks in Atrial Fibrillation: Let's Talk About Sex. <i>Canadian Journal of Cardiology</i> , 2019, 35, 145-146.	0.8	1
1602	To the Editor—Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?. <i>Heart Rhythm</i> , 2019, 16, e56.	0.3	1

#	ARTICLE	IF	CITATIONS
1603	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13092.	1.7	1
1604	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008160.	1.4	1
1605	Response by Chao et al to Letter Regarding Article, "Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study". <i>Circulation</i> , 2019, 139, 146-147.	1.6	1
1606	Risk assessment and management of atrial fibrillation patients with left atrial thrombus. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1-3.	0.5	1
1607	Editorial commentary: Reversal agents in the era of non-vitamin k antagonists oral anticoagulants: Necessity or psychological crutch?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 91-92.	2.3	1
1608	What is the impact of the latest ACC/AHA and ESC/ESH guidelines on the management of hypertension in the UK?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1123-1125.	0.9	1
1609	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. <i>IJC Heart and Vasculature</i> , 2020, 26, 100461.	0.6	1
1610	Stroke risk stratification in hypertrophic cardiomyopathy. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 318-320.	0.4	1
1611	Detection of Atrial Fibrillation on Stroke Units: Look Harder, Look Longer, Look in More Sophisticated Ways. <i>Cerebrovascular Diseases</i> , 2020, 49, 656-658.	0.8	1
1612	Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. <i>Future Cardiology</i> , 2020, 16, 585-595.	0.5	1
1613	Short-Term Apixaban for Documented Left Atrial Appendage Thrombus in High-Risk Atrial Fibrillation Patients Undergoing Left Atrial Appendage Occlusion. <i>TH Open</i> , 2020, 04, e351-e353.	0.7	1
1614	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	0.6	1
1615	Avoiding Stroke: A Continuous Monitoring Challenge. <i>Cerebrovascular Diseases</i> , 2020, 49, 121-123.	0.8	1
1616	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 387-388.	2.3	1
1617	Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs "real-world". <i>International Journal of Clinical Practice</i> , 2021, 75, e13888.	0.8	1
1618	End-Stage renal disease and 30-day mortality for adults with and without COVID-19. <i>European Journal of Internal Medicine</i> , 2021, 83, 93-95.	1.0	1
1619	Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. <i>TH Open</i> , 2021, 05, e35-e42.	0.7	1
1620	Atrial fibrillation and cognitive decline: it takes more than an irregular heart beat, to beat the brain. <i>Age and Ageing</i> , 2021, 50, 1891-1893.	0.7	1

#	ARTICLE	IF	CITATIONS
1621	Should we make the risk stratification process more complex in patients with atrial fibrillation?. <i>Europace</i> , 2021, 23, 978-978.	0.7	1
1622	Atrial fibrillation and vascular disease: Coronary artery disease and/or peripheral artery disease?. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 173-175.	0.7	1
1623	In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events. <i>Annals of Internal Medicine</i> , 2021, 174, JC43.	2.0	1
1624	Frailty and cognitive impairment are not reasons to withhold anticoagulation in people with atrial fibrillation but screening could guide management. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1807-1810.	1.3	1
1625	Analysis of the ESC/EACTS 2020 Atrial Fibrillation Guidelines With Perioperative Implications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	1
1626	Quality of care and risk of incident atrial fibrillation in patients with newly diagnosed heart failure: a nationwide cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 539-547.	1.8	1
1627	Disparities in atrial fibrillation management: Is race to blame?. <i>International Journal of Cardiology</i> , 2021, 331, 118-119.	0.8	1
1628	A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF). <i>International Journal of Clinical Practice</i> , 2021, 75, e14313.	0.8	1
1629	Procedural complications in patients undergoing catheter ablation for atrial fibrillation: let's talk about sex. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 427-428.	1.8	1
1630	Exercise-based cardiac rehabilitation for cardiac implantable electronic device recipients. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	1
1631	Relationship between Chronic Kidney Disease, Time-in-Therapeutic Range, and Adverse Outcomes in Atrial Fibrillation: A post hoc Analysis from the AMADEUS Trial. <i>Cerebrovascular Diseases</i> , 2021, , 1-7.	0.8	1
1632	Fusion of Higher Order Spectra and Texture Extraction Methods for Automated Stroke Severity Classification with MRI Images. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8059.	1.2	1
1633	Utilizing biomarkers in atrial fibrillation: the pros and cons. <i>Cardiovascular Research</i> , 2022, 118, 2035-2036.	1.8	1
1634	Effect of Training on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 770.	3.8	1
1635	Disparities in atrial fibrillation: a call for holistic care. <i>Lancet Regional Health - Europe, The</i> , 2021, 7, 100160.	3.0	1
1636	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. <i>European Journal of Internal Medicine</i> , 2021, 91, 75-80.	1.0	1
1637	Antithrombotic therapy in chronic liver disease: to clot or not to clot. <i>Lancet Regional Health - Europe, The</i> , 2021, 10, 100226.	3.0	1
1638	Atrial Fibrillation and Heart Failure: How Should We Manage Our Patients?. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 162.	1.3	1

#	ARTICLE	IF	CITATIONS
1639	Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?. Current Vascular Pharmacology, 2014, 12, 373-383.	0.8	1
1640	OUP accepted manuscript. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	1
1641	Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention. Kardiologia Polska, 2020, 78, 512-519.	0.3	1
1642	Predicting Mortality in Patients with Atrial Fibrillation and Obstructive Chronic Coronary Syndrome: The Bialystok Coronary Project. Journal of Clinical Medicine, 2021, 10, 4949.	1.0	1
1643	Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2. Russian Journal of Cardiology, 2020, 25, 4179.	0.4	1
1644	Revisiting the diagnosis of "resistant hypertension": what should we do nowadays? Journal of Human Hypertension, 2022, 36, 337-340.	1.0	1
1645	Atrial fibrillation (acute onset). Clinical Evidence, 2011, 2011, .	0.2	1
1646	Management of Atrial Fibrillation in Patients With Kidney Disease. Journal of Atrial Fibrillation, 2014, 6, 989.	0.5	1
1647	Stroke And Bleeding Risk Assessment: Where Are We Now?. Journal of Atrial Fibrillation, 2014, 6, 1042.	0.5	1
1648	Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. Journal of Geriatric Cardiology, 2020, 17, 612-620.	0.2	1
1649	Screening for Atrial Fibrillation: Improving Efficiency of Manual Review of Handheld Electrocardiograms. Engineering Proceedings, 2020, 2, 78.	0.4	1
1650	Warfarin and increased fracture risk? Answering the big question. Age and Ageing, 2022, 51, .	0.7	1
1651	Season of Birth and Cardiovascular Mortality in Atrial Fibrillation: A Population-Based Cohort Study. Journal of Cardiovascular Development and Disease, 2021, 8, 177.	0.8	1
1652	A Rollercoaster Plunge into 2022. Thrombosis and Haemostasis, 2022, 122, 001-004.	1.8	1
1653	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	1.0	1
1654	Outcome of Femoral Angioplasty/Stenting Procedures in Different Ethnic Groups in England: A Retrospective Analysis of Hospital Episode Statistics and Review of Literature. Journal of Endovascular Therapy, 2022, , 152660282110709.	0.8	1
1655	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. International Journal of Clinical Practice, 2022, 2022, 1-8.	0.8	1
1656	Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation with Concomitant Hyperthyroidism: A National Discharge Database Study. Journal of Clinical Medicine, 2022, 11, 1342.	1.0	1

#	ARTICLE	IF	CITATIONS
1657	COVID-19 and COVID-19 vaccination: Observations on thrombosis and thrombocytopenia. Trends in Cardiovascular Medicine, 2022, , .	2.3	1
1658	Thoracic aortic aneurysms and atrial fibrillation: commonality in pathophysiological pathways. Cardiovascular Research, 2022, 118, e32-e35.	1.8	1
1659	Left Atrial Appendage Occlusionâ€™A Choice or a Last Resort? How to Approach the Patient. Interventional Cardiology Clinics, 2022, 11, 135-142.	0.2	1
1660	Prognosis of Atrial Fibrillation with or without Comorbidities: Analysis of Younger Adults from a Nationwide Database. Journal of Clinical Medicine, 2022, 11, 1981.	1.0	1
1661	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. European Journal of Internal Medicine, 2022, 98, 122-124.	1.0	1
1662	Crizanlizumab. JACC Basic To Translational Science, 2021, 6, 946-947.	1.9	1
1663	Bridging the Gap Between Artificial Intelligence Research and Clinical Practice in Cardiovascular Science: What the Clinician Needs to Know. Arrhythmia and Electrophysiology Review, 2022, 11, e03.	1.3	1
1664	Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. International Journal of Clinical Practice, 2022, 2022, 1-9.	0.8	1
1665	Airborne Occupational Exposure and ABO Phenotype: An Example of Gene-Environment Interaction in Ischaemic Heart Disease?. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 179-182.	3.1	0
1666	Autonomic reflexes in heterotopic heart transplantation. International Journal of Clinical Practice, 2004, 58, 520-522.	0.8	0
1667	Matrix metalloproteinases in atrial fibrillation. Journal of the American College of Cardiology, 2004, 43, 152.	1.2	0
1668	Anticoagulation for Stroke Prevention. Pharmacoeconomics, 2006, 24, 1035-1038.	1.7	0
1669	Pharmacotherapy for atrial fibrillation: is rhythm control achievable?. Expert Opinion on Pharmacotherapy, 2006, 7, 1105-1107.	0.9	0
1670	Aortic elasticity, left ventricular geometry and diastolic dysfunction in hypertension. International Journal of Clinical Practice, 2006, 60, 1337-1340.	0.8	0
1671	Blood pressure control and prevention of stroke. Expert Review of Neurotherapeutics, 2006, 6, 203-212.	1.4	0
1672	Atherosclerotic Renal Artery Stenosis â€™Do We Really Know What To Do?. Blood Pressure, 2007, 16, 288-290.	0.7	0
1673	Is it the post-challenge hyperglycaemic spike or arterial stiffness we should be screening for?. International Journal of Clinical Practice, 2007, 61, 356-358.	0.8	0
1674	Cardioversion of atrial fibrillation: from guidelines to contemporary clinical practice. International Journal of Clinical Practice, 2007, 61, 714-716.	0.8	0

#	ARTICLE	IF	CITATIONS
1675	Assessment of endothelial function: implications for hypertension and cardiovascular disorders. Expert Review of Cardiovascular Therapy, 2009, 7, 561-563.	0.6	0
1676	Response to the letter by Dr Jolobe: "Risk factors and stroke risk stratification for atrial fibrillation: Limitations and new possibilities" American Heart Journal, 2009, 157, e7.	1.2	0
1677	Statins and prophylaxis of venous thrombosis - a further link between arterial and venous thrombosis. International Journal of Clinical Practice, 2010, 64, 1326-1328.	0.8	0
1678	Insights from the new European Society of Cardiology guidelines for the medical management of atrial fibrillation. International Journal of Clinical Practice, 2010, 64, 1587-1590.	0.8	0
1679	Editors choice: recent highlights from the journal of human hypertension. Journal of Human Hypertension, 2010, 24, 775-778.	1.0	0
1680	Dronedaron: NICE enough?. Expert Review of Cardiovascular Therapy, 2010, 8, 1049-1051.	0.6	0
1681	Dronedaron. American Journal of Cardiovascular Drugs, 2011, 11, 355-356.	1.0	0
1682	Comments on the Spanish Society of Cardiology Critical Review of the ESC 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 390-391.	0.4	0
1683	Do the current atrial fibrillation guidelines for stroke prevention need to be changed with the availability of new data on the new oral anticoagulants?. International Journal of Clinical Practice, 2012, 66, 422-424.	0.8	0
1684	A New Era of Oral Anticoagulation in Atrial Fibrillation: Implications in Clinical Practice. Hospital Practice (1995), 2013, 41, 61-70.	0.5	0
1685	Atrial fibrillation "more than simply being irregularly irregular. International Journal of Clinical Practice, 2014, 68, 408-409.	0.8	0
1686	Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention. International Journal of Clinical Practice, 2015, 69, 1334-1340.	0.8	0
1687	Simultaneous computerised activation of the primary percutaneous coronary intervention pathway reduces out-of-hours door-to-balloon time but not mortality. International Journal of Cardiology, 2015, 186, 226-230.	0.8	0
1688	Response by Nielsen and Lip to Letter Regarding Article, "Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA ₂ DS ₂ -VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke" Circulation, 2016, 134, e389-e390.	1.6	0
1689	Letter by Nielsen et al Regarding Article, "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1: Systematic Review and Meta-Analysis" Stroke, 2016, 47, e193.	1.0	0
1690	Response. Chest, 2016, 149, 1590-1591.	0.4	0
1691	Chronic Osteomyelitis and Atrial Fibrillation: Revisiting the Link Between Inflammation Burden and Arrhythmia. Canadian Journal of Cardiology, 2016, 32, 1366-1368.	0.8	0
1692	Response to: The Cause of the Arteriolar Injury in Malignant Hypertension. American Journal of Hypertension, 2017, 30, e15-e15.	1.0	0

#	ARTICLE	IF	CITATIONS
1693	All Types of Hemorrhagic Stroke Are Not Created Equallyâ€”Reply. JAMA Internal Medicine, 2017, 177, 1399.	2.6	0
1694	P3509Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Atrial Fibrillation patients.The FANTASIIA Registry. European Heart Journal, 2018, 39, .	1.0	0
1695	P2297How could non-vitamin K antagonist oral anticoagulants change clinical practice for stroke prevention and improve outcomes in patients with newly-diagnosed atrial fibrillation?. European Heart Journal, 2018, 39, .	1.0	0
1696	P3850Refining stroke and bleeding risk prediction by adding consecutive biomarkers to CHA2DS2-VASc and HAS-BLED scores. European Heart Journal, 2018, 39, .	1.0	0
1697	P1885CHA2DS2VASc score predicts exercise capacity in patients with permanent atrial fibrillation and preserved left ventricular function. European Heart Journal, 2018, 39, .	1.0	0
1698	P5139Identification of atrial fibrillation patients who are at high bleeding risk after undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial. European Heart Journal, 2018, 39, .	1.0	0
1699	P5140Geographic region, stroke risk and renal function strongly affect treatment choice for stroke prevention in patients with non-valvular AF: results from the GLORIA-AF registry program. European Heart Journal, 2018, 39, .	1.0	0
1700	P6589The impact of hypertension on stroke and mortality in patients with atrial fibrillation: the loire valley atrial fibrillation project. European Heart Journal, 2018, 39, .	1.0	0
1701	P3862A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics. European Heart Journal, 2018, 39, .	1.0	0
1702	235Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: prospective validation of the EHRA classification in a nationwide cohort study. European Heart Journal, 2018, 39, .	1.0	0
1703	P1882Relationship between inflammation and atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. European Heart Journal, 2018, 39, .	1.0	0
1704	P5143The increased risk of stroke, bleeding and mortality with new-onset atrial fibrillation in critically ill patients: a nationwide cohort study. European Heart Journal, 2018, 39, .	1.0	0
1705	P6240Long term cardiovascular risk prediction in Real-World atrial fibrillation patients: Validation of the 2MACE score in the FANTASIIA registry. European Heart Journal, 2018, 39, .	1.0	0
1706	4366Estimated effectiveness and safety of non-vitamin K antagonist oral anticoagulants compared to optimally anticoagulated real-world atrial fibrillation patients taking acenocoumarol. European Heart Journal, 2018, 39, .	1.0	0
1707	P5759Renal function stratification and outcomes following catheter ablation of patients with atrial fibrillation. European Heart Journal, 2018, 39, .	1.0	0
1708	Letter by Shahid and Lip Regarding Article, â€œStroke Risk Factors Unique to Womenâ€• Stroke, 2018, 49, e290.	1.0	0
1709	P4816Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes in the daily practice. European Heart Journal, 2018, 39, .	1.0	0
1710	P2298High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI. European Heart Journal, 2018, 39, .	1.0	0

#	ARTICLE	IF	CITATIONS
1711	Are Alpha-Adrenergic Receptor Antagonists Beneficial to Prevent Heart Failure?. JACC: Heart Failure, 2018, 6, 926-927.	1.9	0
1712	P2913 Change in CHA2DS2-VASc score (delta CHA2DS2-VASc score) and the risk of thromboembolism over 12-years follow-up in initially low-risk patients with first-diagnosed atrial fibrillation. European Heart Journal, 2018, 39, .	1.0	0
1713	1360 Incident comorbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): how frequent should we reassess stroke risk in these patients?. European Heart Journal, 2018, 39, .	1.0	0
1714	1460 Effect of the INR stability characteristics on bleeding events among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial. European Heart Journal, 2018, 39, .	1.0	0
1715	P982 Is there an obesity paradox for adverse outcomes in patients with atrial fibrillation? insights from the FANTASIA registry. European Heart Journal, 2018, 39, .	1.0	0
1716	P2905 Antiplatelet therapy use in atrial fibrillation patients taking oral anticoagulation: an analysis of adverse outcomes from the FANTASIA registry. European Heart Journal, 2018, 39, .	1.0	0
1717	Triple or dual antithrombotic therapy post-percutaneous coronary intervention: Which one is better?. Journal of Cardiovascular Electrophysiology, 2019, 30, 2473-2474.	0.8	0
1718	3052 Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries. European Heart Journal, 2019, 40, .	1.0	0
1719	Venous thromboembolism prophylaxis strategies for patients undergoing elective total knee replacement. Lancet Haematology, 2019, 6, e496-e497.	2.2	0
1720	The Liverpool Centre for Cardiovascular Science. European Heart Journal, 2019, 40, 957-958.	1.0	0
1721	Etiological Research Using Observational Data, and Net Clinical Benefit. Simplicity and Practicality Matter. American Journal of Medicine, 2019, 132, 671-672.	0.6	0
1722	Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA2DS2-VASc and Support for CHADS-65. Canadian Journal of Cardiology, 2019, 35, 547-549.	0.8	0
1723	P4779 High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban. European Heart Journal, 2019, 40, .	1.0	0
1724	P4780 Effectiveness and safety of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. European Heart Journal, 2019, 40, .	1.0	0
1725	P1026 Risk factors for the occurrence of stroke after atrial fibrillation ablation. European Heart Journal, 2019, 40, .	1.0	0
1726	P3789 Circulating biomarkers of myocardial fibrosis and cellular apoptosis in patients with atrial fibrillation and heart failure with preserved ejection fraction. European Heart Journal, 2019, 40, .	1.0	0
1727	P1886 Validation of the MB-LATER score prediction ability for recurrent atrial fibrillation after electrical cardioversion. European Heart Journal, 2019, 40, .	1.0	0
1728	P4800 Estimated effect of NOACs compared to Vitamin K Antagonists in real-world atrial fibrillation patients: Data from FANTASIA Registry. European Heart Journal, 2019, 40, .	1.0	0

#	ARTICLE	IF	CITATIONS
1729	Differences in outcomes between oral anticoagulation “new starters” and “switchers” in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials. <i>Journal of Arrhythmia</i> , 2019, 35, 815-820.	0.5	0
1730	Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 97-98.	0.4	0
1731	Anticoagulación oral en pacientes con fibrilación auricular e insuficiencia renal terminal: ¿qué es lo más apropiado? Respuesta. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 97-98.	0.6	0
1732	CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension. <i>Journal of Human Hypertension</i> , 2020, 34, 411-412.	1.0	0
1733	Stroke-Related Visual Impairment; is There an Association with Atrial Fibrillation?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105186.	0.7	0
1734	Physical activity or fitness as medicine for your arteries?. <i>International Journal of Clinical Practice</i> , 2020, 74, e13688.	0.8	0
1735	Letter by Ding et al Regarding Article, “Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation”. <i>Stroke</i> , 2020, 51, e361-e362.	1.0	0
1736	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 331-345.	0.4	0
1737	Letter by Guo et al Regarding Article, “SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation”. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006635.	0.9	0
1738	Wearable cardioverter-defibrillator in patients at risk of sudden cardiac death: consensus document from Kalarus et al. contradicts current guideline recommendations” Authors’ reply. <i>Europace</i> , 2020, 22, 1442-1443.	0.7	0
1739	Atrial fibrillation in obesity: Weighing up the evidence for catheter ablation. <i>Clinical Cardiology</i> , 2020, 43, 1064-1066.	0.7	0
1740	Revisiting the dynamic risks of incident atrial fibrillation: does the use of nonsteroidal anti-inflammatory drugs contribute to risk?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 77-78.	0.2	0
1741	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors’ reply. <i>Europace</i> , 2020, 22, 1600-1601.	0.7	0
1742	Defibrillators for prevention from sudden cardiac death: is it that easy? Authors’ reply. <i>Europace</i> , 2020, 22, 1298-1299.	0.7	0
1743	Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?. <i>American Journal of Medicine</i> , 2021, 134, 67-75.e5.	0.6	0
1744	Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?. <i>SN Applied Sciences</i> , 2021, 3, 1.	1.5	0
1745	Atrial Fibrillation and Oral Health. <i>Arrhythmia and Electrophysiology Review</i> , 2021, 10, 7-9.	1.3	0
1746	Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs. <i>JAMA Network Open</i> , 2021, 4, e219175.	2.8	0

#	ARTICLE	IF	CITATIONS
1747	Response to a letter by Jolobe: ARISTOPHANES subgroup analysis of frail and older patients with NVAF receiving low doses of novel oral anticoagulants. <i>Journal of Internal Medicine</i> , 2021, 290, 221-222.	2.7	0
1748	A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score. <i>Future Cardiology</i> , 2021, 17, 685-692.	0.5	0
1749	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
1750	Changes in antithrombotic treatment in patients with abdominal aortic aneurysmal disease and incident atrial fibrillation: a population-based case-crossover analyses. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
1751	Response to Comment on Choi et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: a Nationwide Population-Based Study. <i>Diabetes Care</i> 2021;44:1393-1401. <i>Diabetes Care</i> , 2021, 44, e199-e199.	4.3	0
1752	Atrial fibrillation in the presence of chronic kidney disease: To ablation or not to ablate. <i>International Journal of Clinical Practice</i> , 2021, 75, e14723.	0.8	0
1753	Antithrombotic therapy: what the dental surgeon has to know. <i>Faculty Dental Journal</i> , 2010, 1, 92-98.	0.0	0
1754	Influence of age on respiratory modulation of muscle sympathetic nerve activity and blood pressure in humans. <i>FASEB Journal</i> , 2013, 27, 1118.23.	0.2	0
1755	Rheumatoid arthritis and autonomic function (1132.10). <i>FASEB Journal</i> , 2014, 28, 1132.10.	0.2	0
1756	Authors'™ reply to Beales. <i>BMJ, The</i> , 2016, 532, i266.	3.0	0
1757	Resumption of antiplatelet therapy in patients with primary intracranial haemorrhage: Balancing benefits and risks. <i>Journal of the Neurological Sciences</i> , 2018, 384, 139-140.	0.3	0
1758	Tackling anti-coagulation under-prescription in the elderly. <i>Aging</i> , 2019, 11, 1070-1072.	1.4	0
1759	The year in cardiology: arrhythmias and pacing™The year in cardiology 2019. <i>Cardiologia Croatica</i> , 2020, 15, 132-145.	0.0	0
1760	Dual antithrombotic therapy on early clinical outcomes in patients with atrial fibrillation after percutaneous coronary intervention: a nationwide study in the era of NOAC. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
1761	Atrial fibrillation (acute onset). <i>Clinical Evidence</i> , 2014, 2014, .	0.2	0
1762	Can venous thromboembolism navigate the prevention of cardiovascular complications?. <i>Annals of Translational Medicine</i> , 2015, 3, 116.	0.7	0
1763	Screening for Atrial Fibrillation: Improving Efficiency of Manual Review of Handheld Electrocardiograms. <i>Engineering Proceedings</i> , 2020, 2, 78.	0.4	0
1764	Reply to "Digoxin and beta-blockers in patients with heart failure™. Letter regarding the article "Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure™. <i>European Journal of Heart Failure</i> , 2022, 24, 239-241.	2.9	0

#	ARTICLE	IF	CITATIONS
1765	Sleep Duration May Not Have Any Effect on The Risk of Stroke: Insights from Mendelian Randomization and Prospective Cohort Studies. Archives of Medical Science, 2021, , .	0.4	0
1766	Impact of mental health conditions on anticoagulation prescription in people with atrial fibrillation. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	1.8	0
1767	CHA 2 DS 2 -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. European Journal of Clinical Investigation, 2021, , e13717.	1.7	0
1768	Atrial Fibrillation Diagnosed following Stroke: Dealing with a New Clinical Entity or Just a Matter of Definition?. Cerebrovascular Diseases, 2021, , 1-3.	0.8	0
1769	Symptom Status, Clinical Subtypes, and Prognosis in Patients With Atrial Fibrillation from the Middle East Region (from the Gulf-SAFE Registry). American Journal of Cardiology, 2022, , .	0.7	0
1770	The impact of socioeconomic deprivation on the risk of atrial fibrillation in patients with diabetes mellitus: a nationwide population-based study. European Heart Journal, 2022, 43, .	1.0	0
1771	The Reply. American Journal of Medicine, 2022, 135, e59-e60.	0.6	0
1772	Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long enough?. Hamostaseologie, 2009, 29, 96-101.	0.9	0
1773	Editors' Choice papers in Thrombosis and Haemostasis. Thrombosis and Haemostasis, 2015, 113, 217-20.	1.8	0
1774	Zero-burden atrial fibrillation: does stroke risk diminish the longer a person is free from atrial fibrillation?. Europace, 2022, , .	0.7	0
1775	What Cannot Be Missed: Important Publications on Electrophysiology in 2021. Arrhythmia and Electrophysiology Review, 2022, 11, e01.	1.3	0
1776	Dronedaron vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 363-371.	1.4	0
1777	444â€fEpidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. European Heart Journal Supplements, 2021, 23, .	0.0	0
1778	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. Journal of Thrombosis and Thrombolysis, 2022, , 1.	1.0	0
1779	Adherence to the 4S-AF Scheme in the Balkan region: Insights from the BALKAN-AF survey. Kardiologia Polska, 2022, 80, 461-467.	0.3	0
1780	Monocytes are increased in pregnancy after gestational hypertensive disease. Scientific Reports, 2022, 12, .	1.6	0
1781	Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease. JAMA Cardiology, 0, , .	3.0	0